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The functional protein microarray is a powerful and versatile systems biology and 
proteomics tool that allows the rapid activity profiling of thousands of proteins in parallel. 
Applications of functional protein microarrays range from the identification of protein-
binding properties, to surveying targets of posttranslational modifications, to uncovering 
novel enzymatic activities. Since the development of the yeast proteome microarray over 10 
years ago [1], more recent work has seen the development of complete and near-complete 
proteome arrays representing viruses, bacteria and plants [2-4]. However, most existing 
human protein microarrays are comprised of only a minority of the human proteome [5-9]. 
We have recently developed a human proteome microarray, the HuProt array, which includes 
nearly 20,000 full-length human proteins [10].  
SUMOylation is an essential posttranslational modification in most organisms that is 
thought to function through its ability to modulate the protein-protein interactions of a 
SUMO target protein. Accordingly, the function of SUMOylation can be better understood 
through the identification of SUMO-modified targets as well as downstream SUMO-
interacting proteins. Recently, we have conducted SUMOylation assays using the HuProt 
microarray to identify numerous previously uncharacterized SUMO E3 ligase-dependent 
substrates using a subset of human SUMO E3 ligases. In order to identify novel SUMO-
interacting proteins, we developed a SUMO-binding assay using the human proteome 
microarray. We then integrated SUMO-binding and SUMOylation data, as well as protein-
protein interaction data from publicly available databases to perform network motif analysis. 
We focused on a single network motif we termed a SUMOmod PPI (SUMO-modulated 
Protein-Protein Interaction) that included the INO80 chromatin remodeling complex subunits 
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TFPT and INO80E. We validated the SUMO-binding activity of INO80E and that TFPT is a 
SUMO substrate both in vitro and in vivo. We then went on to demonstrate a key role for 
SUMOylation in mediating the interaction between these two proteins, both in vitro and in 
vivo. By demonstrating a key role for SUMOylation in regulating the INO80 chromatin 
remodeling complex, this work illustrates the power of bioinformatics analysis of large 
datasets in predicting novel biological phenomena.  
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The concept of microarrays was developed from an earlier concept termed ambient 
analyte immunoassay, first introduced by Roger Ekins in 1989. In the following decade, 
microarrays were first successfully realized as DNA or oligonucleotide microarrays, which 
allowed the quantification of the mRNA expression levels of thousands of genes in parallel. 
This technology has changed many aspects of biological research. Though extremely 
successful, the chemistry of DNA hybridization precludes its application for studying 
proteins, which are considered the major driving force in cells. Consistent with this view, 
mRNA profiles do not always correlate with protein expression as reported in many recent 
mass spectrometry studies [11-13]. Therefore, protein microarrays were developed as a high-
throughput tool to overcome the limitations of DNA microarrays, and to provide a versatile 
platform for protein functional analyses [8, 14, 15].  
 
At the beginning of the development of protein array technology, bacterial strains of a 
cDNA expression library were gridded and grown on nylon membranes, followed by lysis of 
the bacteria and immobilization of the total protein complement [17, 18]. However, these 
early attempts only had limited success, because 1) heterologous proteins (e.g., human 
proteins) were expressed in bacteria, yielding proteins that lacked critical eukaryotic 
posttranslational modifications; 2) denaturing conditions were used to lyse the bacterial host, 
resulting in improperly folded proteins; 3) proteins of interest were not purified away from 
thousands of unwanted bacterial proteins; and 4) the density of the array was low. Before 
long, other research groups began to report their efforts to fabricate high-density protein 
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microarrays with purified proteins or antibodies [19-22]. In order to improve protein stability 
and preserve the native conformation of purified proteins, many research groups developed a 
variety of surface features to keep proteins hydrated during protein microarray fabrication. 
These efforts included reports on 3D gel-pad chips [23], nanowell chips [21], and plasma 
membrane-coated chips [24], to name a few.  
 
The real breakthrough was a 2001 report on the fabrication of a yeast proteome 
microarray by the Snyder group [25]. In this study, approximately 5,800 full-length yeast 
ORFs were individually expressed in yeast and their protein products purified as N-terminal 
GST-fusion proteins. Then, each purified protein was robotically spotted on a single glass 
slide in duplicate at high-density to form the first “proteome” microarray, as it covered more 
than 75% of the yeast proteome. More recently, proteome microarrays have been fabricated 
from the proteomes of viruses, bacteria, plants, and humans [2-5, 8, 10, 26]. 
 
On the basis of their applications, protein microarrays can be divided into two classes: 
analytical and functional protein microarrays [27]. Unlike antibody arrays (analytical 
microarrays), functional protein microarrays are made by spotting purified proteins on solid 
surfaces and are therefore useful for direct characterization of protein functions, such as 
protein binding properties, posttranslational modifications, enzyme-substrate relationships, 
and immune responses [28]. More recently, a reverse-phase array was developed in which 




Meanwhile, we and others have developed various types of biochemical assays that 
can be conducted using protein microarrays to characterize protein-binding properties, 
including protein-protein, -DNA, -RNA, and, -lipid interactions, and to identify substrates of 
various types of enzymes, such as protein kinases, acetyltransferases, and ubiquitin and 
SUMO E3 ligases via covalent reactions [1, 19, 30-37] (Table 1).  These efforts clearly 
demonstrate the versatility and power of protein microarray technology as a systems biology 
and proteomics tool. In this review, we will summarize recent applications of protein 
microarrays in clinical proteomics, including biomarker identification, pathogen-host 
interactions, and cancer biology (Table 2). 
 
1.2. Biomarker identification 
 
One of the most rapidly growing applications of protein microarray technology in the 
field of clinical proteomics is biomarker identification. This application for protein 
microarrays stemmed from traditional serology studies, which focus on the diagnostic 
identification of antibodies in patient serum samples. These antibodies can be produced as 
part of an immune response to an infection, against a foreign protein, or even against a 
person’s own proteins. When proteins on a protein microarray are viewed as potential 
antigens, researchers can use it as a platform to identify autoantibodies that show statistically 
significant association with an infection or with a disease of interest. In general, the 
following approach is used: first, patient sera are diluted (e.g., 1000-fold) and incubated on a 
pre-blocked antigen microarray (i.e., protein microarray), followed by a stringent washing 
step. Then, positive signals are detected using anti-human IgG, IgM, or IgA antibodies 
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Table 1. Protein Microarray Studies by Posttranslational Modification 
 




Yeast 87 yeast kinases [1, 32] 
Human Human CDK5, CKII [39, 40] 
Four herpesvirus kinases [41] 
Arabidopsis Arabidopsis MAPKs [4, 26] 
Herpesvirus EBV BGLF4 [42] 
 
Ubiquitylation 
Yeast HECT-domain E3 Rsp5 [34, 43] 
Human HECT-domain E3 Nedd4  
& Nedd4L 
[44] 
Acetylation Yeast NuA4 complex [33, 35] 
E. coli PAT [45] 
SUMOylation Human SAE1/SAE2, Ubc9 [36] 
S-nitrosylation Yeast & Human N/A [46] 
 
 
coupled with various fluorophores for detection (Figure 1). Compared with traditional 
serology techniques, such as ELISA, agglutination, precipitation, complement-fixation, and 
fluorescent antibodies, protein microarray-based serum profiling is much more sensitive and 
can be performed at a much higher throughput. Another significant advantage is that it offers 
an unbiased platform for novel biomarker identification. In this section, we will review four 





In 2003, Zhu et al fabricated the first viral proteome microarray composed of every 
 6 
 
Table 2. Protein Microarray Studies in Clinical Proteomics 
 
Disease 




Serum antibodies detected on SARS-CoV arrays 
comprised of ~60 purified proteins of 5 coronaviruses  [2] 
B cell lymphoma or 
AIDS-related 
Kaposi's lymphoma 
Serum antibodies detected on herpesvirus array 
comprised of ~80 purified EBV and KSHV proteins [47] 
Rabbit model of 
Plague 
Rabbit serum antibodies detected on Yersinia pestis 
arrays comprised of 149 proteins [48] 
Brucellosis  
Serum antibodies detected on Brucella melitensis 
arrays comprised of 3046 proteins expressed in 
lysates [49] 
Cervical carcinomas 
or precursor lesions 
Serum antibodies detected on papillomavirus arrays 
comprised of 154 proteins of 13 viruses  [50] 
Streptococcus 
infection 
Human proteins detected on Streptococcal surface 
protein arrays comprised of 201 purified proteins 




Disease (CD and 
UC) 
Serum antibodies detected on E. coli K12 arrays 
comprised of purified 4,179 proteins [51] 
Autoimmune 
Hepatitis 
Serum autoantibodies detected on human arrays 
comprised of 5011 purified proteins [52] 
Primary Biliary 
Cirrhosis 
Serum autoantibodies detected on human arrays 
comprised of ~17,000 purified proteins [53] 
Sjögren’s syndrome 
Saliva autoantibody detected on human arrays 
comprised of ~8,000 purified proteins  [54] 
Cancer 
Breast Cancer 
Serum autoantibodies detected on human arrays 
comprised of 4988 candidate tumor antigens [55] 
Cancer stem-like cell glycan signature identified 
using array of 94 lectins [56] 
Bladder Cancer 
Serum autoantibodies detected on human arrays 
comprised of ~8,000 purified proteins [57] 
Rhabdomyosarcoma 
Phosphorylation status of 27 proteins detected on 








Figure 1. Principle of serum profiling assays performed on a functional protein 
microarray. A functional protein microarray, composed of hundreds of thousands of 
individually purified proteins, is first blocked with BSA in PBS buffer. Then, a diluted serum 
sample is incubated on the microarray typically at RT for 1 hr. After extensive washes, 
bound antibodies (e.g., human IgG, IgA, or IgM) can be detected with anti-human 
immunoglobulin antibodies, followed by a signal amplification step with fluorescently 
labeled secondary antibodies. Detection of immunoglobulin isotypes can be multiplexed with 
different fluorophores as illustrated. 
 
full-length protein and protein fragment encoded by SARS coronavirus (SARS-CoV), as well 
as proteins from five additional mammalian coronaviruses [2]. These microarrays were then 
used to screen 400 Canadian serum samples collected during the 2002 SARS outbreak, 
including samples from confirmed SARS-CoV cases, respiratory illness patients, and 
healthcare professionals. Antibody response was quantified by the application of both anti-
human IgG and IgM antibodies each coupled to different fluorophores, followed by 
measurement of fluorescence signal intensity (Figure 2). To identify potential biomarkers, 













A protein microarray Detection of antigens Signal amplification 
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serum samples were first clustered according to the relative signal intensities of all of the 
coronavirus proteins in an unsupervised fashion (See Data Analysis section). The serum 
samples fell into two major groups, which upon subsequent comparison with clinical data 
were largely correlated with either SARS-positive or SARS-negative sera. In the cluster of 
markers, five fragments of the SARS N protein associated tightly with SARS infection, while 
SARS sera also exhibited statistically significant binding to one spike protein fragment. 
However, a few proteins encoded by other coronaviruses also showed significant correlation. 
To determine the best classifiers and classification model, two different supervised analysis 
approaches, k nearest neighbor (k-NN) and logistics regression (LR) were applied, and the N 
protein of SARS CoV, as well as the spike protein S from both SARS CoV and HCoV-229E, 
were identified as the best classifiers. A useful feature of a serum test relative to a nucleic 
acid diagnostic test is that anti-pathogen antibodies can potentially be detected long after 
infection. Taking advantage of this, serum samples collected from SARS patients, who 
recovered from respiratory disease (~320 days after diagnosis), were used to probe the 
microarray and positive signals were detected with both anti-human IgG and IgM antibodies 
(Figure 2; middle panel). These results clearly showed that SARS CoV N proteins could be 
readily recognized by human IgG antibodies and importantly, not by IgM antibodies, as 
expected. However, serum samples collected from the Chinese patients immediately after 
fever was detected showed much stronger signals both in the IgG and IgM profiling (Figure 
2; left panel). These results indicated that the protein microarray approach is capable of 
detecting anti-pathogen antibodies in serum samples long after infection, as well as detecting 
infection at early stages of infection as demonstrated by anti-human IgM profiling. The 
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approach developed here is potentially applicable to all viruses and expected to have a great 
impact on epidemiological studies and possibly in clinical diagnoses. 
 
 
Figure 2. Examples of IgG and IgM profiles obtained with serum samples of SARS-
CoV-infected patients.  Sample FP B0352 was collected immediately following detection of 
fever in a patient in Beijing; Sample DP C08 was collected from a recovered SARS patient in 
Toronto. Signals in the upper panel and the BSA control were detected with anti-human IgGs, 
while signals in the lower panel of the two patient samples were detected with anti-human 
IgMs. 
 
Humoral immune responses to herpesviruses 
 
A similar approach has been applied to profile humoral immune responses to two 
human herpesviruses, Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus 
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(KSHV). EBV is a ubiquitous human herpesvirus, while KSHV has a restricted 
seroprevalence. Both viruses are associated with malignancies and show an increased 
frequency in individuals who are co-infected with human immunodeficiency virus type 1 
(HIV-1). The Zhu and Hayward groups generated a protein microarray consisting of 174 
EBV and KSHV full-length proteins that were individually expressed and purified from yeast 
[42, 47]. Instead of sera, plasma antibody responses to EBV and KSHV were examined from 
healthy volunteers and patients with B cell lymphoma or with AIDS-related Kaposi's 
sarcoma or lymphoma. These experiments detected IgG responses to known antigens, as well 
as the tegument proteins ORF38 (KSHV), BBRF (EBV), BGLF2 (EBV), and BNRF1 (EBV), 
and to the EBV early lytic proteins BRRF1 and BORF2. Because IgA responses to EBV 
EBNA1 and viral capsid antigens have long been used as a diagnostic tool for 
nasopharyngeal carcinoma, they also found IgA responses in healthy and HIV-infected 
patients. IgA responses to VCA and to EBNA1 were found to be frequently elevated in 
lymphoma patients and in individuals who were HIV-1 positive. Comparison between the 
IgG and IgA responses indicated that IgA responses were much higher against BCRF1, 
BRRF2, and LMP2A.  Therefore, this study demonstrated that plasma can be used for 
biomarker identification; immunoglobulin responses of other isotypes, such as IgA, are 
therefore also worth testing.  
 
E. coli proteome microarrays for IBD diagnosis 
 
To demonstrate that protein microarrays could also be used to identify new 
biomarkers in autoimmune diseases, Chen et al decided to apply an E. coli K12 proteome 
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microarray [3] to profile serum samples collected from Crohn’s disease (CD) and ulcerative 
colitis (UC) patients [51]. CD and UC are chronic, idiopathic, and clinically heterogeneous 
intestinal disorders collectively known as inflammatory bowel disease (IBD). Although IBDs 
have been suggested to be autoimmune diseases, anti-microbial antibodies are present in the 
sera of IBD patients, and some of these antigens have proven to be valuable serological 
biomarkers for diagnosis and/or prognosis of the disease. In this study, a protein microarray, 
including 4,256 proteins encoded by a commensal K12 strain, was screened using individual 
serum from healthy controls (n = 39) and clinically well-characterized patients with IBD (66 
CD and 29 UC). Surprisingly, among the 417 E. coli proteins that were differentially 
recognized by serum antibodies from healthy controls and either CD or UC patients, 169 
proteins were identified as highly immunogenic in healthy controls, 186 proteins were 
identified as highly immunogenic in CD patients, and only 19 proteins were identified as 
highly immunogenic in UC patients. Using several statistical tools, they identified two sets of 
serum antibodies as novel biomarkers for specifically distinguishing CD from healthy 
controls (accuracy, 86±4%; p < 0.01) and CD from UC (accuracy, 80±2%; p < 0.01). This 
study was the first demonstration of using high-density, high-content proteome microarrays 
to discover novel serological biomarkers. It was also the first effort to examine human 
immune responses to the entire proteome of a microbial species in a disease context. 
 
Autoantigen discovery for AIH 
 
A protein microarray composed of individually purified human proteins would be an 
ideal tool for discovery of novel autoantigens associated with an autoimmune disease. Take 
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autoimmune hepatitis (AIH) as an example: AIH is a chronic necroinflammatory disease of 
human liver with little known etiology. Detection of non-organ-specific and liver-related 
autoantibodies using immunoserological approaches has been widely used for diagnosis and 
prognosis. However, these traditional autoantigens, such as anti-SMA (smooth muscle 
autoantibodies) and anti-ANA (antinuclear autoantibodies) are often mixtures of complex 
biological materials. Unambiguous and accurate detection of the disease demands 
identification and characterization of these autoantigens. Therefore, Song et al fabricated a 
human protein microarray of 5,011 non-redundant proteins that were expressed and purified 
as GST fusions in yeast [36]. There are several advantages associated with producing human 
proteins in yeast rather than bacteria: 1) higher solubility, 2) higher yields of large proteins 
(e.g. > 50 kD), 3) better preserved conformation of proteins, and 4) proteins are less 
immunogenic when produced in yeast than in E. coli [3, 10, 31]. However, unlike a viral or 
bacterial protein microarray, a significant obstacle to the use of a human protein microarray 
of high content is its high cost. For example, a human protein array of 9,000 proteins can 
exceed $1000 per array. In order to reduce this cost, Song et al developed a two-phase 
strategy to identify new biomarkers in AIH. Phase I is designed for rapid selection of 
candidate biomarkers, which are then validated in Phase II (Figure 3). In Phase I, 30 AIH and 
30 control serum samples were selected and individually used to probe the human protein 
microarrays at a 1000-fold dilution, followed by detection of bound human autoantibodies 
using a Cy-5-conjugated anti-human IgG antibody. Statistical analysis revealed 11 candidate 
autoantigens. To validate these candidates and to avoid a potential overfitting problem (see 
below), which is especially likely when dealing with a small sample size, the 11 proteins and 
3 positive controls were re-purified to build a large number of low-cost small arrays for 
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Phase II validation. These arrays were then sequentially probed with serum samples used in 
Phase I and serum samples obtained from an additional 22 AIH, 50 primary biliary cirrhosis 
(PBC), 43 hepatitis B (HB), 41 hepatitis C (HC), 11 system lupus erythematosus (SLE), 11 
primary Sjögren’s syndrome (pSS), and 2 rheumatoid arthritis (RA) patients. As negative 
controls, they also included 26 serum samples from patients suffering from other types of 
severe disease and 50 samples from healthy subjects. Three new antigens, RPS20, Alb2-like, 
and dUTPase, were identified as highly AIH-specific biomarkers with sensitivities of 47.5% 
(RPS20), 45.5% (Alba-like), and 22.7% (dUTPase), which were further validated with 
additional AIH samples in a double-blind design. Finally, they demonstrated that these new 
biomarkers could be readily applied to ELISA-based assays for clinical diagnosis and 
prognosis.  
 
This study represents a new paradigm in biomarker identification using protein 
microarrays for three reasons. First, a manageable number of candidate biomarkers can be 
rapidly identified at low cost because fewer expensive protein microarrays of high-content 
are needed in the first phase of this two-phase strategy. Second, by using small arrays 
comprised of selected candidate proteins, the validation step can be rapidly carried out with a 
much larger cohort at lower cost. This validation step is extremely important for avoiding the 
overfitting problem associated with statistical analysis in biomarker or classifier 
identification, especially when dealing with a small cohort (e.g., <40). 
 
In addition, there have seen a series of studies that employed pathogen protein 
microarrays to profile serological responses following infection. For example, protein 
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microarrays have been developed in bacteria and viruses for biomarker identification in 
various infectious diseases [37-40]. These studies have clearly demonstrated the power of 
protein microarrays in identification of potential biomarkers; however, several shortcomings 
are repeatedly seen in these studies. For instance, many of these arrays were fabricated using 
proteins translated in E. coli lysates without purification [49, 52, 59]. Because these proteins 
are contaminated with unwanted E. coli proteins, sensitivity of the assay is likely reduced due 
to their high immunogenicity [47]. As a result, E. coli lysates had to be used as a blocking 
reagent to alleviate this problem. Also problematic is that in many of these studies, identified  
biomarkers were not validated with additional cohorts and therefore, the possibility of 
overfitting was not completely ruled out. 
 
Figure 3. Scheme of the two-phase autoimmune disease biomarker strategy. In Phase I, a 
small cohort is used to rapidly identify a group of candidate biomarkers via serum profiling 
assays on a human protein microarray of high cost. Because a small number of microarrays 
are needed, cost of the experiments is relatively low. In Phase II, a focused protein 
microarray of low cost is fabricated by spotting down purified candidate proteins. A much 
larger cohort is then assayed on these arrays in a double blind fashion to validate the 






Figure 3. Scheme of the two-phase autoimmune disease biomarker strategy. 
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1.3. Pathogen-host interactions 
 
An emerging application of protein microarrays in the field of clinical proteomics is 
an unbiased, proteome-wide survey of important players involved in pathogen-host 
interactions. The identified factors, encoded by either a pathogen or a host, have the potential 
to be developed into novel therapeutic targets. Protein microarrays can serve as an ideal 
platform for such purposes: Once a protein microarray is fabricated from a host or pathogen, 
it can be used to identify direct pathogen-host interactions. This strategy is particular useful 
for investigating virus-host interactions because after entering the host cells, the viral genome 
and encoded proteins are in direct physical contact with the host’s biological materials. As 
we will discuss in this section, such interactions can be investigated at multiple levels, such 
as RNA-protein interactions, enzyme-substrate relationships, and protein-protein interactions. 
 
BMV RNA and host proteome interactions 
 
In 2007, Zhu et al described the first study using a yeast proteome microarray to 
identify host factors that can affect replication of Brome Mosaic Virus (BMV), a plant-
infecting RNA virus that can also replicate in S. cerevisiae [31].  Previous studies have 
shown that this positive-stranded RNA virus encodes a tRNA-like structure at the 3’-end of 
its RNA genome, in which a clamped adenine motif (CAM) is required for packaging its 
genome into the capsid. To identify crucial host proteins that can interfere with the viral 
packaging process, a Cy3-labeled CAM-containing RNA stem-loop structure was incubated 
on the yeast proteome microarray in the presence of an equal amount of a Cy5-labeled 
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mutated CAM hairpin. Using Cy3-to-Cy5 fluorescence signal intensity ratios, the top hits 
were identified and validated using an in vitro gel-shift assay. Two validated candidate 
proteins, pseudouridine synthase 4 (Pus4) and actin patch protein 1 (App1), were selected for 
further characterization in tobacco plants. Both proteins modestly reduced BMV genomic 
plus-strand RNA accumulation, but dramatically inhibited BMV systemic spread in plants. 
Pus4 also prevented the encapsidation of the BMV RNAs in plants and the reassembly of 
BMV virions in vitro.  
 
This work is significant because it established the first RNA-binding assay on a 
proteome microarray and demonstrated the utility of protein microarrays for identifying 
important players involved in pathogen-host interactions. 
 
Host phosphorylome of virus-encoded kinases 
 
In the course of evolution, viruses have been very successful at exploiting the host via 
development of their own arsenals, some of which were hijacked from the host in the form of 
both DNA and proteins. To develop more effective antivirals, one must understand the 
molecular mechanisms by which viruses exploit the host machineries for their own use. The 
human , , and  herpesviruses infect different tissues and cause distinct diseases, ranging 
from mild cold sores to pneumonitis, birth defects, and cancers [60]. However, they each 
confront many of the same challenges in infecting their hosts, including reprogramming 
cellular gene expression, sensing cell-cycle phase and modifying cell-cycle progression, and 
reactivating the lytic life cycle to produce new virions and spread infection. On the other 
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hand, many lytic cycle genes involved in replication of the viral genomes (e.g., the 
orthologous serine/threonine protein kinases) are highly conserved across the herpesvirus 
family. Therefore, it became an attractive hypothesis that the shared substrates targeted by 
these orthologous viral kinases would reveal host pathways that are critical for replication 
across the herpesvirus familyTo test the above hypothesis, Li et al employed a human protein 
microarray [42]. The authors purified four orthologous kinases encoded by EBV, KSHV, 
HCMV, and HSV-1, performed kinase reactions on a human protein microarray described 
previously [4], and identified 110 shared substrates. Like every large-scale screen, the next 
challenge was to select candidates that would be worth pursuing. To do so, the authors then 
applied Gene Ontology (GO) and STRING analyses (http://string-db.org/, a database of 
known and predicted protein-protein interactions) to these candidates and found a highly 
connected cluster of 15 proteins. Strikingly, these proteins were all known to be involved in 
the DNA damage response (DDR) (Figure 4). The host DDR has been known to be important 
to many viruses, including human herpesviruses, and is relevant to virus-induced 
tumorigenesis [41]. To narrow down this list to a single candidate for in-depth 
characterization, the authors reasoned that the viruses are likely to target an upstream master 
regulator, which triggers the DNA damage response. On the basis of a literature search and 
the structure of this cluster, Tat-interactive protein 60 (TIP60) emerged as an excellent 
candidate for follow-up, because 1) TIP60 is further upstream in the DDR pathway than any 
of the other candidates in the cluster; 2) it serves as a master regulator in DDR via activation 
of ATM autophosphorylation activity by acetylation; 3) it regulates chromatin dynamics via 
histone acetylation; and 4) its importance has been shown in other viruses. Indeed, the 





Figure 4. Identification of most relevant candidate for in-depth in vivo studies. Assisted 
by GO analysis, 110 shared substrates of conserved herpesvirus kinases were plugged into 
the STRING database. A highly connected cluster of 15 proteins was revealed, all of which 
are known to play a role in DDR. Based on the literature and topology of the cluster, TIP60 
emerged as the most promising candidate. Protein nodes are color coded by functional class, 
with proteins involved in DDR colored red. Small blue circles adjacent to protein nodes 
indicate that the protein is herpesvirus associated, while small pink circles indicate the 
proteins are associated with other viruses. Edges between the proteins represent known or 





greatly reduced. Next, the authors applied a series of cell-based assays and showed that 
during EBV replication, TIP60 activation by the BGLF4 kinase triggers EBV-induced DDR 
and also mediates induction of viral lytic gene expression. Finally, the authors demonstrated 
that TIP60 was also required for efficient lytic replication in HCMV, KSHV, and HSV-1.  
 
This work illustrates the value of high-throughput, unbiased approaches for the 
discovery of conserved viral targets in the host that have the potential to be developed into 
novel therapeutic targets for antivirals. Currently, there are few drugs available to treat 
herpesvirus infections, and viral escape mutants develop as a result of extensive use of this 
limited repertoire. The herpesvirus protein kinases are attractive antiviral drug targets. 
However, developing broadly effectively drugs targeting protein kinases requires knowledge 
of their common cellular substrates. The information provided by common substrate 
identification will assist in the design of assays for new and broadly effective anti-
herpesvirus therapeutics. 
 
LANA interactome analysis reveals a role in telomere shortening 
 
Protein microarrays can also serve as a convenient tool for profiling protein-protein 
interactomes between a pathogen and a host. In a recent example, Hayward and colleagues 
surveyed the interactome between a KSHV-encoded virulent factor, LANA, and the human 
host using human protein microarrays, in order to identify host proteins that can be 
recognized by LANA [44]. LANA functions in latently infected cells as an essential 
participant in KSHV genome replication and as a driver of dysregulated cell growth. 
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Although yeast two-hybrid screens, glutathione S-transferase (GST) affinity, 
immunoprecipitation (IP) assays, and chromatography coupled with mass spectroscopy have 
been applied to the identification of LANA binding proteins, each approach has strengths and 
weaknesses, and each tend to identify different sets of proteins. In this study, the authors used 
purified FLAG-tagged LANA applied to human protein microarrays to identify 61 potential 
binding partners, many of which were previously unknown. 8 out of 9 proteins were 
validated by co-immunoprecipitation, including TIP60, protein phosphatase 2A (PP2A), 
replication protein A (RPA) and XPA. Although human papillomavirus (HPV) E6, HIV-1 
TAT, and human cytomegalovirus (HCMV) pUL27 interact with TIP60 and induce TIP60 
degradation, LANA-associated 42 retained acetyltransferase activity and showed increased 
stability. This observation is in line with the study described in the previous section that 
showed that TIP60 plays a positive role in KSHV lytic replication. On the other hand, 
identification of RPA as a LANA interacting partner suggested that LANA may play a role in 
regulating the length of host telomeres, because RPA1 and RPA2 are known to be essential 
in the replication of cellular telomeric DNA. To test this hypothesis, the authors performed 
ChIP assays with anti-RPA1 and -RPA2 antibodies using primers specific to the telomere 
regions and found that the presence of LANA drastically reduced the recruitment of both 
RPA1 and RPA2 to the host telomeres, while it had no impact on the protein level of the 
RPA complex. This observation raised the possibility that LANA might have an impact on 
telomere length. Using Southern blot analysis of terminal restriction fragments, the standard 
method for quantifying telomere length, the authors demonstrated that the average length of 
telomeres was shortened by at least 50% in both LANA-expressing endothelial cells and 
KSHV-infected primary effusion lymphoma cells. Many interesting questions remain to be 
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answered. How does LANA block the RPA complex recruitment to the telomeres? Is it 
achieved via direct competition since LANA is also a ssDNA binding protein? Or, does 
LANA serve as a kinase sink for the RPA complex and regulate RPA recruitment via 
phosphorylation?  
 
SUMO-EBV interactome revealed a new mechanism of EBV lytic replication 
 
On the flip side, a human factor of interest can be used to survey a virus protein 
microarray to identify important viral factors. Similar to the ubiquitylation pathway, 
SUMOylation involves a series of sequential enzymatic reactions that conjugate SUMO to 
lysine residues on substrate proteins. Previous studies have shown that both latent and lytic 
EBV proteins interact with the SUMO system. Noncovalent SUMO-EBV protein interactions 
can occur via a SUMO interaction motif (SIM) in the target proteins. To comprehensively 
identify additional EBV proteins that bind to SUMO, Li et al performed a protein-binding 
assay with human SUMO2 [61] on a previously described EBV proteome microarray [47] 
and identified a total of 11 proteins, including the conserved viral kinase BGLF4. The 
mutation of potential SIMs in BGLF4 at both N- and C-termini changed the intracellular 
localization of BGLF4 from nuclear to cytoplasmic, while BGLF4 mutated in the N-terminal 
SIM remained predominantly nuclear. The mutation of the C-terminal SIM yielded an 
intermediate phenotype with nuclear and cytoplasmic staining. The authors also found that 
BGLF4 abolished the SUMOylation of the EBV lytic cycle transactivator ZTA, and that this 
inhibitory effect on ZTA SUMOylation was dependent on both BGLF4 SUMO binding and 
BGLF4 kinase activity. The global profile of protein SUMOylation was also suppressed by 
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BGLF4 but not by the SIM or kinase-dead BGLF4 mutant. Furthermore, BGLF’s interaction 
with SUMO was required to induce the cellular DNA damage response and to enhance the 
production of extracellular virus during EBV lytic replication. 
 
Identification of novel streptococcal proteins that bind human ligands 
 
 
The identification of pathogen proteins that interact with human factors has also been 
applied to understanding the mechanisms of bacterial infection. Margarit and others 
harnessed the power of protein microarrays to identify proteins expressed by two species of 
the streptococcus gram-positive bacteria, Streptococcus pyogenes and S. agalactiae, that 
interact with human factors known to mediate pathogenesis [62]. Rather than develop whole-
proteome arrays, they used a bioinformatics approach to predict those proteins present on the 
cellular surface—and thus most likely to play a role in infection, and used this list of 200 
proteins to develop their arrays. They also carefully considered the human probes that they 
would use, choosing three human ligands: fibronectin, fibrinogen, and C4 binding protein, all 
known to play important roles in the colonization and infection processes.  Binding 
experiments conducted using the streptococcal arrays and human protein probes identified 17 
of the 20 known interactions previously reported as well as 8 newly identified streptococcal 
proteins, many of which they confirmed by far-western blot analysis.  These novel proteins 
included proteins of unknown function as well as 3 related proteins that they termed the fib 
proteins. They then used domain mapping to identify regions of the fib proteins required for 
their interaction with the human ligands. Interestingly, sera samples from patients with S. 
agalactiae infections show high titers of Fib-specific antibodies, indicating that these 
proteins are highly expressed during infection. Further work will determine the role of these 
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proteins in infection and whether they will emerge as suitable drug targets to fight pathogenic 
Streptoccus infections. 
 
In summary, the above studies have demonstrated the power of protein microarrays in 
the discovery of novel molecular mechanisms underlying host-pathogen interactions at 
various levels. In recent years, other high-throughput approaches, such as shotgun mass 
spectrometry [63], genome-wide RNAi screens [64, 65], and yeast two-hybrid [66, 67] have 
been applied to understand host-pathogen interactions; however, the protein microarray 
approach provides a more versatile platform than any of these single approaches for 
identifying multiple types of direct interactions between a pathogen and host, including 
protein-protein interactions [61, 62, 68], RNA-protein interactions [31], and enzyme-
substrate interactions [41].  
 
1.4. Cancer biology 
 
Over the past five years, rapid development of genome-wide sequencing technologies 
(i.e., next-gen sequencing) has revealed the heterogeneous nature of tumors [69, 70]. 
However, clinical diagnosis of tumors is largely still dependent on morphologic patterns. The 
fact that tumors with indistinguishable morphology can have vastly different clinical 
outcomes suggests that the molecular heterogeneity of each patient’s tumor cells have to be 
better understood before more effective therapies can be developed. Therefore, the future of 
cancer treatment is tailored molecular therapy specific for each individual, which will require 
a new class of proteomic profiling technologies. As a widely adopted technology, protein 
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microarrays can meet this need for the profiling of the functional state of tumors and for 
cancer biomarker identification.  
 
Identification of Autoantibody Biomarkers for the early detection of breast cancer 
 
Current screening for breast cancer using mammograms detects only 70% of breast 
cancers, and false-positive mammograms lead to unnecessary biopsies. The identification of 
biomarkers that would allow early detection of breast cancer could provide a non-invasive, 
low cost method that could improve patient outcomes. One promising category of cancer 
biomarkers are autoantibodies to tumor antigens which offer better stability, specificity, ease 
of purification, and ease of detection compared to other serum proteins. In order to identify 
autoantibodies to tumor antigens associated with breast cancer, Anderson et al. used protein 
arrays containing candidate tumor antigens and applied breast cancer patient and control 
serum samples to identify differences in the human antibody repertoire that could be used as 
biomarkers [55].  These custom protein arrays, termed “NAPPA” arrays (Nucleic Acid 
Protein Programmable Array), are fabricated by the spotting of cDNAs that encode the target 
proteins at each feature of the array. Proteins are transcribed and translated by a cell-free 
system and immobilized by encoded epitope tags, thus bypassing the protein purification 
process. Additionally, the authors used a three-phase screening approach to home in on the 
best candidate breast cancer biomarkers. In the first phase, they used arrays with the full set 
of 4988 tumor antigens in order to eliminate uninformative autoantibodies that were present 
at similar levels in both early breast cancer patients and healthy women. Subtracting these 
antigens, the protein set was reduced to 761, allowing them to fabricate smaller arrays for the 
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next phase that offer the benefits of reduced cost and fewer false positives. In the second 
phase, sera from patients with invasive early breast cancer and benign breast disease were 
compared, in order to identify antigens specific to early breast cancer but absent from benign 
breast disease, resulting in 119 antigens. In the third phase, they set out to validate this 
antigen list, finding 28 antigens that maintained high levels of specificity in a blinded 
validation assay, including the protein ATP6AP1, a known autoantigen. They then focused 
on this protein and went on to show high expression of ATP6AP1 in 4 breast cancer cell lines 
by Western blot, as well as significantly higher ATP6AP1 autoantibody levels in ~13% of 
early breast cancer serum cases compared to controls. Although only a first step, this work 
demonstrates the power of protein microarrays, in particular programmable protein 
microarrays, in identifying biomarkers for the early detection of breast cancer. 
 
Finding autoantibody biomarkers in bladder cancer  
 
An important goal of identifying cancer biomarkers is to define new strategies for 
early diagnosis that can allow early intervention with current therapies to improve patient 
survival rates. Additionally, since cancer-associated autoantibodies often target proteins that 
are mutated, modified, or aberrantly expressed in tumor cells, they could also be considered 
immunologic reporters that could uncover molecular events underlying tumorigenesis [57]. 
The molecular players in these events, in turn, may be the best place to start in efforts to 
develop novel therapies. In order to identify autoantibody biomarkers that could act as 
indicators of bladder cancer, as well as the underlying molecular pathology contributing to 
disease, Orenes-Pinero turned to a protein array strategy using the Invitrogen Protoarray 
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containing ~8,000 purified human proteins to identify antibodies to tumor-associated 
antigens in serum. Comparing serum samples collected from 12 patients with bladder cancer 
and 10 control patients without bladder cancer, they identified 171 differentially expressed 
proteins. Among these, they selected clusterin and dynamin for validation based in part on 
their known role in cancer biology. Using immunohistochemistry on a custom tissue 
microarray comprised of bladder cancer tumor samples, they found reduced expression levels 
of clusterin in muscle invasive bladder tumors as compared to nonmuscle invasive tumors. 
On the other hand, they found that low protein expression of dynamin was associated with 
increased tumor stage and grade, higher recurrence rate after surgery, as well as shorter 
survival. Paradoxically, their follow-up tests revealed lower expression levels of dynamin 
and clusterin associated with disease, in contrast to their protein array results which showed 
increased autoantibody levels to these proteins among bladder cancer patients compared to 
controls. Despite these contradictory findings, the authors demonstrated significant 
associations between dynamin and clusterin expression levels and bladder cancer disease 
progression that could potentially allow them to use these as informative biomarkers in the 
clinic as well as potential drug targets. This work demonstrates the power of protein 
microarrays for the identification of autoantibodies to tumor-associated antigens and its 




 Recent years have witnessed tremendous growth in the use of protein microarrays to 
address important questions in the field of clinical proteomics. In the area of biomarker 
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identification, most of the recent research has been focused on either infections or 
autoimmune diseases. We believe that protein microarrays, especially functional protein 
microarrays, will be widely used for identification of cancer biomarkers in the near future. 
Indeed, recent advances in immunoproteomics and high-throughput technologies have 
suggested that the autoantibody repertoire in cancer patients might be quite different as 
compared with that in healthy subjects, leading to the hypothesis that autoantigens might be 
identified as biomarkers for cancer diagnosis, as well as cancer prognosis [71]. Ideally, a 
human protein microarray developed for such a purpose should cover the entire human 
proteome, in order to enable a comprehensive screen for the autoantigens. To our knowledge, 
we have fabricated a human proteome microarray of the best coverage (>70%) [10]. 
However, when hundreds, if not thousands, of serum samples are needed to screen for 
biomarkers, the cost of using these human proteome microarrays accumulates very rapidly. 
An effective strategy to overcome this obstacle is to apply the two-phase strategy as 
described in the AIH study [7]. We expect that this strategy will become popular in the near 
future. Finally, we expect that functional protein microarrays will be used as a readout to 
obtain reaction profiles of the collected activities of various types of enzymes, such as 
kinases, acetyltransferases, ubiquitin and SUMO E3 ligases in cancerous tissues. Comparing 
PTM profiles obtained from cancer and healthy tissues will allow us to identify biomarkers 

































2.1. The SUMOylation pathway 
 
Posttranslational modifications of proteins provide a central molecular mechanism for 
cells to respond to external stimuli [72]. While phosphorylation is perhaps the best-
characterized posttranslational modification, numerous other modifications play crucial roles 
in cellular responses to their environment. The UBL (ubiquitin-like) family of 
posttranslational modifications is distinct in that it involves attachment of a protein to target 
proteins. Many types of UBLs exist, including ubiquitination, SUMOylation, ISGylation, and 
NEDDylation, URMylation, ATGylation, and FUBIlation. Protein SUMOylation is an 
essential process in most organisms, including S. cerevisiae, C. elegans, Arabidopsis thaliana 
and mice [73]. SUMOylation is the best characterized of the UBL-modifications other than 
ubiquitin itself and has been implicated in regulating a diverse array of protein activities 
including localization, inhibition of transcription factors, inhibition or activation of enzymes, 
as well as stimulating, or preventing, degradation
 
[74]. Despite a large body of literature 
demonstrating a wide range of functions for SUMOylation, many important questions remain 
about its physiological roles in the cell. 
 
SUMOylation was first discovered almost 20 years ago in 6 different labs 
independently. The first publication reporting the existence of SUMO described a genetic 
approach that identified the yeast homolog of SUMO, SMT3, as a genetic suppressor of Mif2, 
a gene involved in mitosis [75]. A year later, another group used a biochemical approach, 
finding that SUMO was covalently linked to the nuclear protein RANGAP1 in rat liver 
nuclear envelopes [76]. That same year, work in the laboratory of Edward Yeh identified a 
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protein that they termed Sentrin as a Tumor necrosis factor death domain-interacting protein 
in a yeast two-hybrid screen [77]. Meanwhile, another yeast two-hybrid assay identified 
SUMO, which they termed PIC1, as a protein that interacted with promyelocytic leukemia 
(PML) protein [78]. In yet a third yeast two-hybrid assay designed to identify proteins that 
interact with RAD51 and RAD52, two proteins involved in DNA recombination and repair, 
the protein was found and termed UBL1, or ubiquitin-like 1, due to its homology with 
ubiquitin [79]. Finally, in 1997, Frauke Melchior and colleagues also described a form of 
RanGAP1 modified by a novel protein, in rat liver extract, HeLa and other human cell lines, 
that they named SUMO-1, the name that would later become the official gene symbol [80]. 
 
While there is a single SUMO paralog in invertebrates, there are 4 SUMO paralogs in 
humans. Whether SUMO4 can be conjugated to target proteins is controversial and as a 
result most SUMO research has focused on the other SUMO paralogs, SUMO1-3. SUMO2 
and SUMO3 share 96% amino acid sequence identity and cannot be distinguished by 
available antibodies. For this reason they are often treated as a single protein, described in the 
literature as “SUMO2/3”. Human SUMO1 shares about 45% sequence identity with SUMO2 
and SUMO3. Although structurally very similar, SUMO1 and SUMO2/3 show some 
functional differences, particularly regarding cellular localization, their role in the formation 
of SUMO polymers or chains, and to what proteins they bind and are conjugated to. SUMO1 
is uniquely found within the nucleoli, nuclear envelope as well as cytoplasmic foci, while 
SUMO2/3 was found to accumulate on chromosomes [81]. Because SUMO2 contains a 
SUMOylation consensus site, it is believed that only SUMO2 can act as an acceptor in the 
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formation of SUMO chains, while SUMO1 is more likely to act as a SUMO chain terminator 
[82]. 
 
A few substrates have been identified that show preferential binding to and/or 
modification by one or other of the SUMO paralogs. For example, Ran GTPase activating 
protein 1 (RANGAP1), is preferentially modified by SUMO1 [83]. Ubiquitin specific 
protease 25 (USP25) and Topoisomerase II are both preferentially modified by SUMO2/3 
[84, 85]. The Bloom’s syndrome helicase protein (BLM) preferentially binds to SUMO2/3 
and this binding is thought to be important for its subsequent SUMO2/3 modification [86].  
 
All UBLs, including SUMOylation, appear to be conjugated to their target proteins by 
similar enzymatic pathways but generally involve distinct enzymes specific to the particular 
UBL. The SUMOylation cycle includes 5 major steps: 1) maturation, in which the C-
terminus of SUMO is removed by a sentrin protease (SENP) to reveal a reactive diglycine 
motif, 2) activation, in which SUMO is first adenylated and then transferred to a cysteine on 
the SUMO E1 heterodimer UBA2/AOS1, 3) conjugation, in which SUMO is transferred to a 
cysteine on the E2 enzyme UBC9, 4) ligation, in which SUMO is attached to a target protein 
lysine by UBC9, often in coordination with a SUMO E3 ligase and finally 5) deconjugation, 







2.2. Role of SUMO E3 ligases in SUMOylation specificity 
 
Although a SUMOylation consensus motif has been described that frequently 
provides a site for SUMO attachment to proteins, increasing numbers of proteins have been 
identified with SUMOylation sites not contained within this consensus motif. The 
SUMOylation consensus motif sequence, described as Kx(D/E), in which  represents a 
hydrophobic residue, has been shown to bind directly to the SUMO E2 enzyme UBC9, and 
this direct interaction may explain why the SUMO E1 enzyme and UBC9 alone are sufficient 
to SUMOylate many substrates in vitro. However, many substrates show enhanced 
SUMOylation in the presences of a SUMO E3 ligase and it has been proposed that SUMO 
E3 ligases may be particularly important for SUMOylation of susbtrates in vivo and 
especially at nonconsensus SUMOylation sites. Furthermore, as the only classes of 
SUMOylation enzymes for which multiple members have been identified, the SUMO E3 
ligases and the SUMO proteases have been proposed to be the major factors determining 
substrate specificity.  
 
Although there is a lack of consensus in the literature as to the total number of bona 
fide SUMO E3 ligases, most reported E3s can be divided into three major groups: those that 
lack any clear consensus motif, those that contain a RING domain, and those that contain a 
related motif known as an SP-RING domain. SUMO E3 ligases that feature an SP-RING 
motif may or may not require it for their function, depending on the substrate [87-92]. E3s in 
this class are characterized by direct binding to their respective targets, the SUMO E2 
enzyme UBC9 as well as SUMO itself. The SP-RING motif containing SUMO E3 ligases are 
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comprised of the human homolog of the yeast protein Mms21, known as NSE2, as well as 
the PIAS family proteins, PIAS1-4. Included in the category of SUMO E3 ligases that lack 
any consensus motif is the best characterized SUMO E3 ligase, RANBP2, which is believed 
to function by stimulating release of SUMO from the SUMO charged-UBC9 thioester 
complex. SUMO E3 ligases that contain a RING domain include TOPORS and MUL1, two 
proteins that had been first identified as ubiquitin E3 ligases and were then found to 
additionally possess SUMO E3 ligase activity [93, 94]. There are currently nearly 617 genes 
predicted to encode ubiquitin E3 ligases [95]. While there is no clear consensus in the 
literature on the number of bona fide SUMO E3 ligases, the most liberal estimate would be 
under 30. Due to the similarities between the ubiquitylation and sumoylation pathways, it is 
predicted that more SUMO E3 ligases remain to be identified. 
 
2.3. Non-covalent interactions with SUMO 
 
Although SUMOylation can regulate a diverse array of protein activities, at the 
molecular level SUMOylation alters protein surfaces and their ability to interact with other 
proteins [73]. It has been proposed that SUMO is a molecular glue that mediates non-
covalent interactions between modified substrates and SUMO-binding proteins [96]. This has 
been demonstrated for the interaction between promyelocytic leukemia (PML) protein and 
thymine DNA glycosylase (TDG), in which SUMO-modification as well as SUMO-
interaction motifs on both proteins promote their interaction. They found that the PML 
binding activity of SUMO1-modified TDG was 2.5-fold greater than that of the unmodified 
form in an in vitro assay. They also found that TDG interacted more strongly with the 
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wildtype form of PML as opposed to the PML(3KR) SUMOylation-defective mutant. These 
results corroborate the idea that SUMOylation promotes the interaction between TDG and 
PML.  
 
The transcription factors P300 and Elk-1 each recruit specific HDACs following 
modification by SUMO1 [97-99]. Another SUMO-mediated protein-protein interaction has 
been described for RanGAP1 and RANBP2. In this example, SUMO1 modification functions 
to target RanGAP1 to the nuclear pore complex through stimulating its interaction with 
RanBP2 [100]. The interaction between the DNA helicase Srs2 and  SUMO-modified PCNA 
recruits Srs2 to replication forks and prevents recombination events during DNA replication 
[101].  
 
The first SUMO interaction motif (or SIM) was identified through yeast two-hybrid 
experiments that identified the SUMOylation enzyme SAE2, PML and the PIAS proteins as 
SUMO interactors [102]. Alignment of the amino acid sequences of these proteins revealed a 
SUMO interaction motif consisting of an S-X-S motif preceded by hydrophobic amino acids 
and followed by acidic amino acids. Revisiting this proposed SIM and the importance of 
individual amino acids that comprise this SIM, subsequent work using NMR found that the 
S-X-S sequence was less important than the hydrophobic residues and defined a new SUMO 
interaction motif as V/I-X-V/I-V/I [103]. Later, another yeast two-hybrid focused on the 
identification of proteins interacting with both SUMO1 and SUMO2 isoforms identified 20 
SUMO interacting proteins. Amino acid sequence alignment and subsequent NMR validation 
supported the importance of a hydrophobic core sequence as well as acidic residues that 
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could either precede or follow this hydrophobic core, which would determine the orientation 
of the SUMO and SUMO binding protein interaction [104]. Zinc finger motifs have recently 
been described as a second type of distinct SUMO interaction motif [105, 106]. 
 
2.4. SUMO in human disease 
 
SUMO has been shown to be linked to devastating neurodegenerative diseases 
including Huntington’s and Parkinson’s diseases, usually in the context of promoting target 
protein solubility and preventing the formation of aggregates that are correlated with disease 
[107, 108]. SUMOylation has also been linked to cardiovascular disease. Recently, it was 
shown that SUMO gene therapy improved cardiac function in mice with heart failure by 
promoting the stability of a cardiac calcium ATPase [109]. Finally, the study of 
SUMOylation is likely to yield important insights into cancer development and therapeutics. 
High expression levels of a de-SUMOylation enzyme have been correlated with prostate 
tumor growth and metastasis [110]. SUMO has found to have many roles in different types of 
DNA damage repair, a process which if better understood could allow the development of 
more targeted and less toxic chemotherapeutics [111]. 
 
2.5. Screens to identify SUMO binding proteins 
 
 Takahashi et al used a yeast two-hybrid approach to identify SUMO1 binding 
proteins [96] and found 5 proteins. Among these included two proteins known to be SUMO-
modified, Sp100 and TDG, two proteins known to be involved in SUMO-conjugation, Uba2 
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and PIAS3, as well as one protein with no previously known interaction with SUMO, EBI3. 
However, the scope of their study was limited by the use of only the SUMO1 isoform as bait 
and the use of only 3 types of cDNA libraries, including libraries derived from two immune 
cell types from mouse, B and T cells, and one library derived from human brain. 
 
The following year, Hecker et al also used a yeast two-hybrid approach to identify 
SUMO binding proteins, but this time expanded the screen to look at both SUMO1 and 
SUMO2 paralogs as bait, with cDNA libraries derived from three human tissue types, 
including thymus, spleen and kidney. They identified 20 proteins including 8 previously 
known to interact with SUMO and 8 novel SUMO interactors [104]. Among these, most 
interacted equally with both SUMO1 and SUMO2, except for two proteins. RANBP2, which 
showed a clear preference for interacting with SUMO1, and TTRAP, which interacted more 
strongly with SUMO2 than SUMO1.  
 
Ouyang et al used an affinity purification strategy using HeLa nuclear extracts to 
isolate proteins that interacted with GST-SUMO2 and identify these proteins by mass 
spectrometry [112]. This approach identified 107 SUMO interacting proteins, representing a 
large increase in the total number of known SUMO binders. However, this study missed 
many other potential SUMO interactors including all proteins with subcellular localization 

















The INO80 Chromatin Remodeling Complex and Roles of SUMOylation in Chromatin 
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3.1. The INO80 Chromatin Remodeling Complex 
 
The INO80 chromatin remodeling complex is a 15 subunit complex that has been 
implicated in the regulation of transcription, checkpoint regulation, chromosome segregation, 
telomere maintenance, as well as DNA repair and replication [113]. Functional analysis of 
INO80 chromatin remodeling activity in yeast has primarily focused on its role in histone 
subunit exchange, while studies of the orthologous mammalian complex have demonstrated a 
role in nucleosome sliding [114, 115]. The human INO80 complex contains 6 metazoan-
specific subunits, including the deubiquitylating enzyme UCH37, TFPT, INO80D, INO80E, 
MCRS1, and NFRKB, and these subunits are associated with the N-terminal domain of 
INO80. Although this N-terminal domain is not essential for nucleosome sliding, it has been 
proposed that these subunits are likely to have regulatory roles in vivo [116].   
 
3.2. The INO80 Complex Subunit TFPT 
 
Although TFPT had been proposed to play a regulatory role as a subunit of the 
INO80 complex, its function in this context is unknown. Analysis of TFPT function has 
mostly focused on its role apart from the INO80 complex, and its role in stimulating 
apoptosis and localization to the nucleus. TFPT was first described in the context of its 
involvement in a chromosomal aberration underlying pre-B-cell acute lymphoblastic 
leukemia. This chromosomal aberration resulted in a protein fusion with the transcription 
factor TCF3, which is the basis for the standard gene symbol TFPT [117]. Subsequently, 
TFPT was found to interact with the protein Arc and drive its nuclear import [118]. TFPT has 
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also been shown to stimulate apoptosis and associate with other apoptosis-inducing proteins 
[119, 120]. There is some evidence to suggest TFPT may function as a transcription factor. 
TFPT was reported to contain a b-ZIP domain [121], and BLAST analysis of the TFPT 
amino acid sequence reveals that it has 30% sequence identity with the transcription factor 
DNA damage-inducible transcript 3 protein, with particularly high homology to the leucine 
zipper motif in this protein. TFPT was found to possess sequence-specific DNA binding 
activity in a screen for DNA binding proteins using a transcription factor protein microarray 
[122]. Many transcription factors have been reported to be SUMO-modified, and 
SUMOylation in many cases has been shown to regulate their transcription factor activity. 
There is both indirect and direct evidence to support the SUMOylation of TFPT. TFPT was 
found to associate with Arc, a protein that accumulates in PML bodies, which are highly 
enriched with SUMOylated proteins [123, 124]. TFPT was identified as a target of SUMO2 
in an affinity-purification and mass-spectrometry study [125]. Recently, TFPT was shown to 
be SUMO-modified at K216, which is contained within a SUMOylation consensus site [126]. 
 
3.3. The INO80 Complex Subunit INO80E  
 
Much less is known about the INO80 complex subunit INO80E. It was found to be 
associated with the transcription factor FOXP3 in T cell hybridoma cells in an affinity-
purification mass spectrometry screen [127]. Protein expression was found in the liver, retina 
and multiple immune system cell types based on a recent effort to “map” the human 





3.4. SUMOylation in Chromatin Remodeling 
 
A wide range of chromatin modifying enzymes and chromatin associated proteins 
have been found to possess SUMO-binding activity or be regulated in some way by 
SUMOylation [97]. The interaction between the histone deacetylase HDAC2 and the 
transcription factor Elk-1 was shown to be enhanced by SUMOylation, resulting in 
recruitment of the enzyme to DNA and subsequent histone deacetylation [99]. The SETDB1 
methyltransferase was shown to interact with the SUMOylated form of the KAP-1 
corepressor, and reduced KAP-1 SUMOylation was correlated with reduced SETDB1 
genome occupancy and H3K9 trimethylation levels [129]. The nucleosome remodeling 
enzyme Mi-2 was found to bind directly to SUMO and SUMO modified Sp3, and Mi-2 target 
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The functional protein microarray is a powerful and versatile systems biology and 
proteomics tool that allows the rapid activity profiling of thousands of proteins in parallel. 
We have recently developed a human proteome array, the HuProt array, which includes 
~80% of all the full-length proteins of the human proteome. In one recent application of the 
HuProt array, we identified numerous SUMO E3 ligase-dependent SUMOylation substrates. 
For many SUMO E3 ligases, only a small number of substrates have been identified and the 
target specificities of these ligases therefore remain poorly defined. In this protocol, we 
outline a method we developed using the HuProt array to screen the human proteome to 




The functional protein microarray is a powerful and versatile systems biology and 
proteomics tool that allows the rapid activity profiling of thousands of proteins in parallel. 
Applications of functional protein microarrays range from the identification of protein-
binding properties, to surveying targets of posttranslational modifications, to uncovering 
novel enzymatic activities. Since the development of the yeast proteome microarray over 10 
years ago [1], more recent work has seen the development of complete and near-complete 
proteome arrays representing viruses, bacteria and plants [2-4]. However, most existing 
human protein microarrays are comprised of only a minority of the human proteome [5-9]. 
We have recently developed a human proteome microarray, the HuProt array, which includes 
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nearly 20,000 full-length human proteins [10]. The proteins used to generate this microarray 
were expressed in yeast and purified under native conditions. Expressing recombinant 
eukaryotic proteins in yeast improves the likelihood that proteins will retain their biological 
activity relative to prokaryotic and in vitro expression systems.  
 
Numerous collaborations between our labs and others have so far harnessed the 
power of the HuProt array to profile a wide range of protein activities. The role of 
posttranslational modifications in regulating enzymatic activity is one area of investigation 
particularly well suited for the HuProt array platform. A screen to define the S-nitrosylated 
proteome revealed an important regulatory role for this posttranslational modification in the 
control of ubiquitin E3 ligase activity [131]. In other work, phosphorylation and 
glycosylation states of the protein kinase CK2 were shown to affect its substrate specificity 
[40]. The HuProt array has also been used in two separate studies to link novel protein-RNA 
interactions to neurological disease, including an interaction between RNA splicing factors 
and a long noncoding RNA linked to schizophrenia [132] and an interaction between 
multiple RNA binding proteins and an expanded repeat-containing transcript implicated in 
amyotrophic lateral sclerosis [133]. Another ongoing project in our labs is the generation of 
monospecific monoclonal antibodies whose specificity can be quickly evaluated using the 
HuProt array [10]. The utility of the HuProt array further extends to exciting clinical 
applications including the identification of novel biomarkers that may be used as a diagnostic 
tool in primary biliary cirrhosis, an autoimmune disease of the liver [53].  
Protein SUMOylation is an essential posttranslational modification in most organisms, 
including yeast, C. elegans, Arabidopsis, and mice [73]. The reversible SUMO-modification 
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of target proteins involves an enzymatic cascade chemically similar to ubiquitylation, 
involving E1 activating, E2 conjugating, E3 ligating enzymes and SUMO proteases. As the 
only classes of SUMOylation enzymes for which multiple members have been identified, the 
SUMO E3 ligases and the SUMO proteases have been proposed to be the major factors 
determining substrate specificity. Recently, we have conducted SUMOylation assays using 
the HuProt microarray to identify numerous previously uncharacterized SUMO E3 ligase-
dependent substrates using a subset of human SUMO E3 ligases. While our study focused on 
some of the best characterized SUMO E3 ligases, recently additional SUMO E3 ligases have 
been described [134-138] and it is likely that new SUMO E3 ligases await discovery [139]. 
The methods that we describe here could be used to identify substrates for these additional 
SUMO E3 ligases. For most SUMO E3 ligases, only a limited number of substrates are 
known. In this chapter, we will describe the on-chip SUMOylation protocol that we have 
developed so that the reader may conduct SUMOylation assays using the HuProt microarray 





1. HuProt human proteome microarray (CDI Laboratories, USA). 
2. Bench-top centrifuge (Thermo Scientific: HERAEUS Multifuge 3SR+ 
centrifuge). 
3. Four-well dish (NUNC 267061). 
 46 
 
4. Humidity chamber (USA Scientific pipet tip box with wet paper towels 
inside). 
5. Laboratory tissues (Kimwipes). 
6. LifterSlip Coverslips (Fisher: 22035809) 
7. Micro slide boxes (VWR 48444-004) 
8. Microarray analysis software, GenePix Pro 6.0 (MDS Analytical 
Technologies) 
9. Orbital shaker. 
10. GenePix 4000B Microarray Scanner (Molecular Devices, USA) 
 
4.3.2. Purification of the SUMO E1 enzyme 
1. E1 Binding Buffer: 20 mM Tris-HCl pH 8.0, 350 mM NaCl, 1mM beta-
mercaptoethanol, 10 mM imidazole. 
2. E1 Wash Buffer: 20 mM Tris-HCl pH 8.0, 350 mM NaCl, 1mM beta-
mercaptoethanol, 20 mM imidazole. 
3. E1 Elution Buffer: 20 mM Tris-HCl pH 8.0, 350 mM NaCl, 1mM beta-
mercaptoethanol, 400 mM imidazole. 
 
4.3.3. Purification of the SUMO E2 enzyme 





4.3.4 Common reagents for expression and purification of SUMO protein and 
SUMOylation enzymes 
1. General lysis buffer: 1X PBS, 1mg/ml lysozyme, 2mM DTT, 1X Roche 
protease inhibitor cocktail (EDTA-free), 10 U/ml benzonase. 
2. Enzyme dialysis buffer: 20mM Tris- -
mercaptoethanol. 
3. PreScission protease (GE Healthcare) 
4. IPTG  
5. 1X PBS 
6. lysozyme powder 
7. 1M DTT 
8. Roche protease inhibitor cocktail (EDTA-free) 
9. Benzonase 
10. Glutathione sepharose (GE Healthcare) 
11. Ni-NTA agarose (Life Technologies) 
 
4.3.5 SUMO Antibody Labeling 
1. SUMO-1 affinity-purified mouse monoclonal antibody (21C7) (#33-2400, 
Life Technologies, USA) 
2. DyLight 549 Antibody Labeling Kit (#53034, Pierce Biotechnology) 
 
4.3.6. On-chip SUMOylation assay 
1. SUMO blocking buffer: 1X TBS pH 7.4, 2% BSA, 0.05% Tween-20. 
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2. 2X SUMO conjugation buffer: 40 mM HEPES pH 7.3, 200 mM NaCl, 20 mM 
MgCl2, 0.2 mM DTT 
3. SUMO reaction mix (for 200ul reaction): 100ul 2X SUMO conjugation 
buffer, 0.25- -




4.4.1. Purification of SUMO Protein 
1. Streak out colonies onto a LB + ampicillin agar plate from a glycerol stock of 
GST-SUMO in pGEX6p.1 in BL21 cells. 
2. Pick a single colony and inoculate into 5 ml LB with ampicillin overnight at 
37°C. 
3. Dilute the 5 ml culture into 50 ml LB with ampicillin culture overnight at 
37°C. 
4. Dilute 50 ml culture into 1 L LB with ampicillin until the OD = 0.6, then drop 
the temperature to 20°C and induce with 1mM IPTG and shake overnight at 
20°C 
5. Freeze pellet at -80°C until ready to proceed with purification. 
6. Thaw pellet at 37°C, resuspend with 25ml general lysis buffer, rotate at RT 
for 15min. 
7. Centrifuge at 4°C for 30min at 14,000rpm to pellet insoluble material. 
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8. During centrifugation prepare glutathione sepharose by washing 2ml 50% 
glutathione sepharose with 1X PBS in 50ml tube.  Repeat 2X. 
9. Bind protein by mixing supernatant with glutathione sepharose, rotate at 4°C 
for 1h or longer. 
10. Wash sepharose by spinning down sepharose, discard supernatant, resuspend 
sepharose in 1ml of 1X PBS.  Transfer sepharose to column; wash with 12ml 
of 1X PBS. 
11. Cleave SUMO from GST tag by transferring sepharose bound with GST-
precission protease and GST-SUMO to the same column.  Parafilm column to 
prevent leakage.  Incubate with shaking at 4°C overnight. 
12. Allow sepharose to settle.  Remove supernatant containing purified untagged 
SUMO.  Apply 4ml of 1X PBS and repeat. 
13. Dialyze overnight against 2 L 1X PBS 
14. Concentrate protein using a micron centrifugal filter (10kDa MWCO) by 
spinning 20 min @ 4000 rpm. Aliquot and freeze with liquid nitrogen and 
store at -80°C. 
 
4.4.2. Purification of SUMO E1 Enzyme 
1. Streak out colonies onto a an LB + ampicillin agar plate from a glycerol stock 
of His-hE1 (His-Aos1/Uba2) in BL21 cells 




3. Dilute the 5 ml culture into 50 ml LB with ampicillin culture overnight at 
37°C. 
4. Dilute 50 ml culture into 1 L LB with ampicillin until the OD = 0.6, then drop 
the temperature to 20°C and induce with 1mM IPTG and shake overnight at 
20°C 
5. Freeze pellet at -80°C until ready to proceed with purification. 
6. Thaw pellet at 37°C, resuspend with 25ml general lysis buffer, rotate at RT 
for 15min. 
7. Centrifuge at 4°C for 30min at 14,000rpm to pellet insoluble material. 
8. During centrifugation prepare Ni-NTA agarose by washing 2ml 50% Ni-NTA 
agarose with E1 binding buffer in 50ml tube.  Repeat 2X. 
9. Bind protein by mixing supernatant with Ni-NTA agarose, rotate at 4°C for 1h 
or longer. 
10. Wash agarose by spinning down agarose, discard supernatant, resuspend 
agarose in 1ml of wash buffer.  Transfer agarose to column; wash with 12ml 
of E1 wash buffer. 
11. Elute with 3 ml of E1 elution buffer. Collect fractions and analyze by SDS-
PAGE. Pool fractions containing protein. 
12. Dialyze overnight against 2 L enzyme dialysis buffer. 
13. Concentrate protein using a micron centrifugal filter (10kDa MWCO) by 
spinning 20 min @ 4000 rpm. Aliquot and freeze with liquid nitrogen and 




4.4.3. Purification of SUMO E2 Enzyme 
1. Streak out colonies onto a an LB + ampicillin agar plate from a glycerol stock 
of GST-Ubc9 in pGEX6p.1 in BL21 cells 
2. Pick a single colony and inoculate into 5 ml LB with ampicillin overnight at 
37°C. 
3. Dilute the 5 ml culture into 50 ml LB with ampicillin culture overnight at 
37°C. 
4. Dilute 50 ml culture into 1 L LB with ampicillin until the OD = 0.6, then drop 
the temperature to 20°C and induce with 1mM IPTG and shake overnight at 
20°C 
5. Freeze pellet at -80°C until ready to proceed with purification. 
6. Thaw pellet at 37°C, resuspend with 25ml general lysis buffer, rotate at RT 
for 15min. 
7. Centrifuge at 4°C for 30min at 14,000rpm to pellet insoluble material. 
8. During centrifugation prepare glutathione sepharose by washing 2ml 50% 
glutathione sepharose with 1X PBS in 50ml tube.  Repeat 2X. 
9. Bind protein by mixing supernatant with glutathione sepharose, rotate at 4°C 
for 1h or longer. 
10. Wash sepharose by spinning down sepharose, discard supernatant, resuspend 
agarose in 1ml of E2 wash buffer.  Transfer sepharose to column; wash with 
12ml of E2 wash buffer. 
 52 
 
11. Cleave UBC9 from GST tag by transferring beads bound with GST-precission 
protease and GST-UBC9 to the same column.  Parafilm column to prevent 
leakage.  Incubate with shaking at 4°C overnight. 
12. Allow sepharose to settle.  Remove supernatant containing purified untagged 
UBC9.  Apply 4ml of E2 wash buffer and repeat. 
13. Dialyze overnight against 2 L enzyme dialysis buffer. 
14. Concentrate protein using a micron centrifugal filter (10kDa MWCO) by 
spinning 20 min @ 4000 rpm. Aliquot and freeze with liquid nitrogen and 
store at -80°C. 
 
4.4.4. SUMO Antibody Labeling 
1. Add 40ul borate buffer to 0.5 ml of 0.5 mg/ml affinity-purified SUMO-1 
antibody. 
2. Add 0.5 ml of antibody in borate buffer to the vial of DyLight reagent and 
vortex gently. 
3. Briefly centrifuge to collect the sample in the bottom of the tube. 
4. Incubate the reaction mixture for 60 minutes at room temperature protected 
from light. 
5. Mix purification resin to ensure uniform suspension and add 400 ul of the 
suspension into both spin columns. Centrifuge for 45 seconds at 1000 g to 
remove the storage solution. Discard the used collection tubes and place the 




sample with the resin by vortexing. 
7. Centrifuge columns for 45 seconds at 1000 g to collect the purified proteins. 
Combine the samples from both columns (0.5 ml total). 
8. Aliquot and store the labeled antibody at -20°C. 
 
4.4.5. On-chip SUMOylation assay 
1. Rinse arrays by quickly dunking in a beaker of 300 mL of TBS. 
2. Place each array in a well of a four-well dish with 3 mL of SUMO blocking 
buffer per well. 
3. Block protein microarray by gently shaking overnight at 4°C.  
4. Prepare the reaction mix and keep on ice.  Add E1 and E2 enzymes and E3 
ligase (optional) immediately before the end of the blocking step. 
5. Remove arrays from blocking buffer and carefully wick off liquid by tapping 
the edge on a paper towel and place arrays in a humidity chamber (See Note 
1). 
6. Add SUMO reaction mix to each slide carefully and place coverslip on top, 
being careful to avoid bubbles. 
7. Incubate at 37°C for 90 minutes (depending on enzyme activity). 
8. Immediately after start of incubation, pre-warm appropriate volume of 1% 
SDS to 55°C for later washing steps. 
9. Remove coverslip by gently sliding off array. 
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10. Place arrays in a large empty pipette tip box (e.g. a 1000ul tip pipette tip box 
works well) and wash gently on orbital shaker 3x for 10 minutes at room 
temperature with enough TBST to completely cover the arrays.  
11. Wash 3 times with 1% SDS warmed to 55°C for 5 minutes. 
12. Wash once with ddH2O. 
13. Dilute labeled SUMO-1 antibody in blocking buffer at 1:1000 dilution. Apply 
200 μL of the antibody mixture to each array and cover with LifterSlip. Place 
arrays in humidity chamber and incubate slides with labeled SUMO-1 
antibody for 1 hour at room temperature. 
14. Remove coverslip by gently sliding off array and wash slides 3 times for 10 
minutes in 50-100 ml TBST in a clean pipette tip box. 
15. Wash the slides once in 50-100 ml milliQ water for 5 minutes to remove 
residual salts from the surface of the microarray. 
16. Place each array horizontally into a micro slide box with laboratory tissues on 
the bottom. Centrifuge the box in a benchtop centrifuge for 3 min at 2000 
rpm. 
17. Scan the microarray with a GenePix 4000B scanner with 5-µm resolution 
detection at 532 nm. Ensure that no spots appear as saturated signals 
(saturated signal appears as white). Save the scanned images as TIF files. All 







1. The humidity chamber is made by placing a folded paper towel in the bottom 
of an empty pipette tip box, adding one inch of ddH2O, and replacing the tip 
holder on the box.  The arrays will sit on the tip holder and be covered with 
the lid. 
2. SUMOylation of many proteins occurs in the absence of E3 ligases at 
relatively high E1 and E2 concentrations, therefore: E1 and E2 concentrations 
should be used in the low end of this range when using an optional E3 ligase. 
When it is desired to omit an E3 ligase, it is recommended to use E1 and E2 





















































Global Analysis of SUMO-Binding Proteins Identifies SUMOylation as a Key Regulator 






















SUMOylation is an essential posttranslational modification in most organisms that is 
thought to function through its ability to modulate the protein-protein interactions of a 
SUMO target protein. Accordingly, the function of SUMOylation can be better understood 
through the identification of SUMO-modified targets as well as downstream SUMO-
interacting proteins. In order to identify novel SUMO-interacting proteins, we developed a 
SUMO-binding assay using the human proteome microarray, which includes nearly 20,000 
full-length human proteins. We then integrated SUMO-binding with a SUMOylation data set 
recently generated in our laboratory, as well as protein-protein interaction data from publicly 
available databases to perform network motif analysis. We focused on a single network motif 
we termed a SUMOmod PPI (SUMO-modulated Protein-Protein Interaction) that included 
the INO80 chromatin remodeling complex subunits TFPT and INO80E. We validated the 
SUMO-binding activity of INO80E and that TFPT is a SUMO substrate both in vitro and in 
vivo. We then went on to demonstrate a key role for SUMOylation in mediating the 
interaction between these two proteins, both in vitro and in vivo. By demonstrating a key role 
for SUMOylation in regulating the INO80 chromatin remodeling complex, this work 
illustrates the power of bioinformatics analysis of large datasets in predicting novel 









The functional protein microarray is a powerful and versatile systems biology and 
proteomics tool that allows the profiling of the activity of thousands of proteins in parallel. 
Applications of functional protein microarrays range from the profiling of protein interaction, 
discovery of posttranslational modifications, and identification of novel enzymatic activities. 
Since the development of the yeast proteome microarray over 10 years ago [1], more recent 
work has seen the development of complete and near-complete proteome arrays representing 
viruses, bacteria and plants [2-4]. However, most existing human protein microarrays are 
comprised of only a minority of the human proteome [5-9]. We have recently developed a 
human proteome microarray, the HuProt array, which includes nearly 20,000 full-length 
human proteins [10]. The proteins used to generate this microarray were expressed in yeast 
and purified under native conditions. Expressing recombinant eukaryotic proteins in yeast 
improves the likelihood that proteins will retain their biological activity relative to 
prokaryotic and in vitro expression systems.  
 
Numerous studies have harnessed the power of the HuProt array to profile a wide 
range of protein activities, including RNA-protein interactions[132, 133], analysis of 
monoclonal antibody specificity [10] and serum profiling [53], and identification of 
substrates of protein kinases [40] and S-nitrosylation [131]. 
 
Recently, we have conducted SUMOylation assays using the HuProt microarray to 
identify numerous previously uncharacterized SUMO E3 ligase-dependent substrates using a 
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subset of human SUMO E3 ligases.  Protein SUMOylation is an essential posttranslational 
modification in most organisms, including yeast, C. elegans, Arabidopsis, and mice [73]. The 
reversible SUMO-modification of target proteins involves an enzymatic cascade chemically 
similar to ubiquitylation, involving E1 activating, E2 conjugating, E3 ligating enzymes and 
SUMO proteases. As the only classes of SUMOylation enzymes for which multiple members 
have been identified, the SUMO E3 ligases and the SUMO proteases have been proposed to 
be the major factors determining substrate specificity.  
 
The ultimate impact of SUMOylation is thought to arise from its ability to modulate 
the protein-protein interactions of a SUMO target. Accordingly, the function of 
SUMOylation is determined through a combination of the identification of SUMO-modified 
targets as well as downstream SUMO-interacting proteins. In order to identify novel SUMO-
interacting proteins, we developed a SUMO-binding assay using the human proteome 
microarray. Previous efforts to identify SUMO-binding proteins have found relatively small 
numbers of proteins [96, 104, 112]. In addition, these studies were limited in that they either 
looked at proteins expressed in a limited number of tissue types, or that they were restricted 
to the identification of proteins localized to the nucleus that bound to only a single SUMO 
isoform. The studies also relied on the use of MS-pulldowns, which are often unable to 
reliably detect low-abundance proteins. For our studies, we utilized the HuProt microarray 
containing nearly 20,000 purified human proteins, thus avoiding bias in favor of particular 
tissue type or subcellular compartment, and allowing identification of low-abundance target 
proteins. We also looked at binding to both SUMO1 and SUMO2 monomers, as well as 
SUMO1 and SUMO2 trimers, which were used as model SUMO chains. Our dataset 
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represents an over 10-fold increase in the number of known SUMO-interacting proteins. The 
vast majority of these proteins had not been previously reported as having SUMO binding 
activity. 
 
To use our data set to make novel predictions about SUMOylation function, we 
integrated our SUMO-binding and SUMOylation data with protein-protein interaction data 
from publicly available databases to perform network motif analysis. We identified 21 three-
component network motifs including 9 network motifs that were significantly enriched and 4 
network motifs that were significantly depleted. We focused on a single network motif 
containing a SUMO-binding protein and a SUMO-modified protein which were previously 
known to interact based on the literature, along with SUMO itself. This specific network 
motif suggests a potential role for SUMO in modulating the protein-protein interaction 
between the other 2 nodes, and we thus termed this motif a SUMOmod PPI (SUMO-
modulated Protein-Protein Interaction). We then validated an example of this network motif 
that comprised INO80 chromatin remodeling complex subunits INO80E and TFPT, along 
with SUMO2. We found that TFPT could be SUMOylated in transfected cells and identified 
the relevant SUMOylation site on the protein. We also validated the SUMO-binding activity 
of INO80E and identified the region of INO80E important for this interaction. Then we went 
on to demonstrate that SUMO helps facilitate the interaction between INO80E and TFPT. 
This work demonstrates the power of bioinformatics analysis of large datasets in predicting 







Previous work reported that the first alpha helix and second beta strand of both 
SUMO1 and SUMO2 can act as a SUMO paralog recognition region that interacts with the 
SIMs of SUMO paralog-specific binding proteins [86, 106, 140]. Although only a handful of 
SUMO paralog-specific binding proteins have been identified to date, structural differences 
in this region suggest that more paralog-specific binding proteins remain to be discovered. In 
order to identify novel SUMO paralog-specific binding proteins we used purified SUMO1 
and SUMO2 monomers as well as SUMO1 and SUMO2 trimers as model SUMO chains 
(Figure 5A) that had been previously used to identify SUMO2-specific binding proteins [86]. 
We then used these protein probes in a novel human proteome microarray-based SUMO-
binding assay (Figure 5B). For detection of SUMO binding proteins on the proteome 
microarray, we prepared fluorescently labeled SUMO-isoform specific monoclonal 
antibodies. We then performed SUMO-binding assays in triplicate for each of the 4 probes. 
Among 461 total SUMO binding proteins that were identified by our assay, only 8 had been 
previously identified in other work (Figure 11). 6 of these 8 previously identified SUMO-
binding proteins were found by a SUMO2-focused affinity purification and mass 
spectrometry based study and include ANXA1, HRNRPK, RUVBL1, TRIM26, ZBED1 and 
ZNF451 [112]. The 4 SUMO protein probes that we tested showed wide variation in their 
binding specificity (Figure 6A). The SUMO2 monomer probe bound to the largest number of 
proteins (306) as well as the largest number of unique proteins (128). The SUMO1 trimer 
bound 197, the SUMO1 monomer bound 183, and the SUMO2 trimer bound 139 proteins in 
total. The pairwise probe combinations of SUMO1 trimer and SUMO2 monomer, and 
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SUMO1 monomer and SUMO2 monomer, each bound the largest and same number of 
proteins (108). On the other hand the SUMO1 trimer and SUMO2 trimer bound to the 
smallest number of shared proteins (66). 39 proteins showed promiscuous SUMO-binding 
activity and interacted with all 4 SUMO probes.  
 
We next conducted gene ontology analysis on the novel SUMO binding proteins 
(Figure 6B). This analysis revealed several notable properties of these proteins. With regard 
to cellular component, we observed significant enrichment for cytoplasmic localization 
among proteins that bound by all four probes.  
 
 
Figure 5. (A) SUMO Probes and SUMO-binding assay. (Top) SUMO1 and SUMO2 
protein surfaces generated using MacPyMOL with previously reported crystal structures of 
SUMO1 and SUMO2, PDB ID 2PE6 and 4BKG, respectively[141, 142]. The surfaces 
corresponding to the first alpha-helix and second beta-strand for both SUMO1 and SUMO2 
are shown in color (nitrogens are shown in red, oxygens in blue and carbons in green). This 
surface has been reported to be important for interactions with other proteins. 
(Bottom) Cartoon showing 4 probes that were used in our experiments. The SUMO1 and 
SUMO2 trimer probes, described previously[86], were expressed as trimeric fusion proteins.  
(B) Schematic of the SUMO-binding protocol used with the human proteome microarray. 
(C) Representative chip images showing human proteome microarray visualized with an 
antibody to GST, showing all proteins (left, in green), and an antibody to SUMO2 following 
a SUMO-binding experiment with the SUMO2 trimer (right, in red) 
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Figure 5. SUMO Probes and SUMO-binding assay  
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Considering that many previously identified SUMO-modified proteins are localized 
to the nucleus, in particular transcription factors, this enrichment of cytoplasmic proteins 
suggests that the importance of SUMOylation in the cytoplasm may be underappreciated. We 
also found that some GO categories were enriched among proteins that bound to all 4 probes 
or a single probe as well as different combinations of 2 or 3 probes. For example, proteins 
associated with the GO category of “actin binding”, “catalytic activity” and “oxidoreductase 
activity” were enriched among targets bound by all 4 probes. A particularly surprising result 
of this analysis was the finding that of all pairwise combinations of probes tested, proteins 
that bound the SUMO1 trimer and SUMO2 monomer, which are two of the most dissimilar 
probes, shared the largest number of molecular function GO categories. With regard to 
biological process, enriched GO categories common to proteins that bound all 4 probes 
included 3 terms: “metabolic process”, “muscle contraction” and “oxidation reduction”. As 
with molecular function, the SUMO1 trimer and SUMO2 monomer binding proteins shared 
the largest number of GO categories compared to any other pairwise probe combination. 
 
We hypothesized that by integrating our SUMO-binding data with recently published 
SUMOylation data [143] as well as protein-protein interaction data from publicly available 
databases, we could make novel predictions about SUMOylation function. Using a network 
motif analysis based bioinformatics approach, we generated a list of 21 tripartite network 
motifs, identifying 9 enriched motifs and 4 depleted motifs (Figure 7). Each motif is 
associated with 2 parameters, including n, the number of examples of the particular motif 
type that we identified, and Z, an enrichment score. This enrichment score is calculated as the 
difference between the observed occurrence of this network motif in the integrated 
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SUMOylation network and its average occurrence in several hundred random networks, 
normalized with the standard deviation [144]. In these network motifs, at least one node 
represents SUMO, and at least one node represents a protein from either the SUMO-binding 
or SUMOylation datasets. These 3 proteins are then connected by edges that represent one of 
three types of protein-protein interaction, including 1) noncovalent SUMO-binding identified 
in our assay or 2) covalent SUMOylation, or 3) a protein-protein interaction from one of 
several publicly available databases. 
 
We then selected one network motif that included two proteins previously reported to 
interact that included a novel SUMO-binding protein (our dataset) and a SUMOylated 
protein [143]. This network motif immediately suggests a potential role for SUMO in 
modulating this protein-protein interaction, thus we termed this network motif a “SUMO-
modulated protein-protein interaction” (SUMOmod PPI). One such SUMOmod PPI 
consisted of the INO80 chromatin remodeling complex subunits INO80E and TFPT, and 
SUMO2. Our proteome microarray assay revealed that INO80E binds specifically to the 




Figure 6. SUMO-binding assay results and gene ontology analysis. 
(A) Venn diagram showing the number of SUMO-binding experiment hits  
(B) Gene ontology analysis on proteins identified in our screen for SUMO-binding proteins. 
Gene ontology categories that are significantly enriched among proteins that bound to one of 
our 4 probes are shown as a colored box, color-coded by probe.  
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Figure 6. SUMO-binding assay results and gene ontology analysis. 
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On the other hand, the other protein, TFPT, was previously found to be specifically 
modified by SUMO2 in the presence of the SUMO E3 ligases PIAS1 and PIAS3 [143]. As a 
candidate “SUMOmod PPI” we hypothesized that SUMO may play a role in modulating the 
interaction between INO80E and TFPT. Before we could proceed with testing our hypothesis 
that SUMOylation may modulate the interaction between the proteins INO80E and TFPT, we 
first wanted to validate their SUMO-binding and SUMOylation properties, respectively, 
using conventional assays. 
 
First, we evaluated the binding of INO80E translated in vitro in rabbit reticulocyte 
lysate in the presence of [
35
S] methionine, to immobilized GST-tagged SUMO-1 or SUMO2 
polymers. We observed a strong interaction between INO80E and the SUMO2 polymer in 
contrast to a very weak, almost undetectable interaction between INO80E and the SUMO-1  
polymer (Figure 12), in agreement with our human proteome microarray data. 
 
 
Visual inspection of the amino acid sequence of INO80E revealed a canonical 
SUMO-interaction motif (SIM) at the protein C-terminus containing a hydrophobic core 
“VIDI” preceded by 3 negatively charged aspartate residues (Figure 8A). In order to test 
whether this predicted SIM was important for SUMO binding, we made 2 mutant forms of 
the INO80E protein. In one mutant, we mutated the hydrophobic residues in the hydrophobic 
core of the SIM to alanines (mtSIM). 
 
Figure 7) Network motif analysis. Schematic of network motif analysis approach showing 
the 3 data sets that were used and all enriched and depleted network motifs. The “SUMOmod 
PPI” network motif that was the focus of subsequent experiments is boxed in orange. 
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Figure 8. INO80E interacts with SUMO in vitro 
(A) Cartoon showing INO80E, the location of the SUMO interaction motif (SIM) at the C-
terminus of the protein and the 2 INO80E. The SIM is color-coded with acidic residues 
shown in red and hydrophobic residues in blue. Note “INO80E SIM” mutant with 
hydrophobic residues mutated to alanines. The “INO80EΔC10” mutant is shown with the 10 
C-terminal amino acids deleted, including acidic and hydrophobic amino acids of the SIM. 
(B) Results from in vitro binding assay. INO80E, the INO80E SIM mutant and the 
INO80EΔC10 were in vitro translated in the presence of [
35
S]-methionine and incubated with 
glutathione sepharose-bound GST-SUMO1 and GST-SUMO2. Following binding, samples 
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were subject to SDS-PAGE and gels were first Coomassie stained to show equal amounts of 
GST-SUMO1 and GST-SUMO2, then dried and exposed to film to detect radiolabeled 
protein. 
 
In the second mutant, we made a truncation mutant that lacked the 10 C-terminal 
residues including the hydrophobic core sequence as well as the preceding negatively 
charged residues (ΔC10). The mtSIM mutant showed a strong reduction in binding of 
INO80E to GST-SUMO2, with only a slight reduction in binding to GST-SUMO1 (Figure 
8B). However, while the INO80E truncation mutant (ΔC10) lacking the 10 C-terminal amino 
acids showed a modest reduction in binding to GST-SUMO1, it showed a dramatic reduction 
in binding to GST-SUMO2, approaching the lower limit of detection in our assay. This result 
demonstrates the importance of both the charged and hydrophobic residues in the interaction 
between INO80E and SUMO, both for SUMO1 and, particularly, for SUMO2. 
 
Next, we turned to the other protein in this network, TFPT. Prior work in our 
laboratory had identified TFPT as being modified by SUMO2 in the presence of the SUMO 
E3 ligases PIAS1 and PIAS3 using a human proteome microarray based assay [143]. 
Additionally, TFPT had been previously shown by others to be modified by SUMO2 in an 
MS-pulldown experiment in HeLa cells [145]. We wanted to validate that TFPT could be 
SUMO-modified in vitro and also identify the lysine residue to which SUMO was attached. 
Amino acid sequence analysis using GPS-SUMO software [146] revealed the presence of a 
consensus SUMOylation motif near the C-terminus of the protein at K216.  To test whether 
this lysine residue was important for SUMOylation we mutated the lysine residue to arginine 
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(K216R). Then we conducted in vitro SUMOylation assays by expressing TFPT in rabbit 
reticulocyte lysate in the presence of [
35
S] methionine followed by incubation with or without 
the E1 and E2 SUMOylation enzymes with either SUMO-1 or SUMO-2 (Figure 9A). When 
wildtype TFPT was incubated with the SUMOylation enzymes and either SUMO1 or 
SUMO2, we observed a strong band representing a 20kD molecular weight shift consistent 
with a SUMO-modified form of TFPT. However, when we incubated the in vitro translated 
TFPT K216R mutant with the SUMOylation enzymes and either SUMO1 or SUMO2, no 
such shifted band was observed. This suggests that K216 is the relevant lysine residue for 
TFPT SUMO-modification by both SUMO isoforms SUMO1 and SUMO2. 
 
Next, we tested the ability of TFPT to be SUMOylated in transfected mammalian 
cells. We co-transfected V5-tagged TFPT with or without myc-tagged SUMO2 into HEK 
293T cells, then immunoprecipitated V5-TFPT using an anti-V5 antibody, followed by 
immunoblotting using an anti-myc antibody to detect SUMOylated TFPT. In the absence of 
myc-SUMO2, no bands were observed in the anti-myc western blot (Figure 9B). However, 
when we co-transfected SUMO2, we saw a strong band representing a SUMO-modified 
TFPT. Next, we tested the ability of the TFPT K216R mutant to be SUMOylated in 
mammalian cells. Although TFPT K216R was expressed (see input V5 blot) at equal levels 
and immunoprecipitated (see IP:V5/IB:V5 blot) with equal efficiency, we failed to see any 
signal in the anti-myc blot, thus indicating that TFPT K216R was not SUMOylated. This 




Previously, our group had shown significant enhancement of TFPT SUMOylation in 
the presence of the SUMO E3 ligases PIAS1 and PIAS3 using human proteome microarray 
based SUMOylation assays [143]. In order to test whether PIAS1 and PIAS3 enhanced 
SUMOylation of TFPT in mammalian cells, we co-transfected either FLAG-tagged PIAS1 or 
untagged PIAS3. When we co-transfected TFPT, SUMO2 and PIAS1, we observed a strong 
signal corresponding to mono-SUMOylated TFPT with several additional bands representing 
several higher molecular weight forms of SUMOylated TFPT . When transfecting the TFPT 
K216R mutant with SUMO2 and PIAS1, the anti-myc immunoblot showed only weak signal 
corresponding to the highest range of molecular weights. 
 
Finally we tested the ability of TFPT SUMOylation to be enhanced by the SUMO E3 
ligase PIAS3. As with PIAS1, we saw a strong band representing mono-SUMOylated TFPT 
as well as a laddering band pattern representing several higher molecular weight forms of 
SUMOylated TFPT. This pattern is not observed when transfecting the TFPT K216R mutant. 
Our results indicate that TFPT is SUMOylated on K216 in mammalian cells, and that the 
SUMO E3 ligases PIAS1 and PIAS3 can stimulate formation of higher molecular weight 
forms of SUMOylated TFPT. We are unable to distinguish whether these high molecular 
weight bands represent the attachment of SUMO2 chains to K216 on TFPT, or alternatively, 
whether SUMOylation at K216 is a necessary event that precedes SUMOylation or even 
other posttranslational modifications at other sites on TFPT. INO80E and TFPT are subunits 
of the human INO80 chromatin-remodeling complex and interact with the N-terminal 
domain of the INO80 ATPase [115]. The SUMOmod PPI network motif containing INO80E, 






Figure 9. TFPT is SUMOylated in vitro and in vivo. 
(A) Results from in vitro SUMOylation assay for TFPT. Wildtype TFPT and the K216R 
mutant were in vitro translated in the presence of [
35
S]-methionine and incubated with our 
without the E1 and E2 SUMOylation enzymes and either SUMO1 or SUMO2.  
 74 
 
(B) Results from the in vivo SUMOylation assay for TFPT. HEK 293T cells were co-
transfected with TFPT and the K216R mutants with or without SUMO2 and either the 
SUMO E3 ligases PIAS1 or PIAS3. We immunoprecipitated V5-tagged TFPT and 
immunoblotted against myc-tagged SUMO2 to detect SUMOylated TFPT. 
 
and TFPT. Considering that the INO80E C-terminal SUMO interaction motif is important for 
the ability of INO80E to interact with SUMO2, and that TFPT is modified by SUMO2, we 
hypothesized that the INO80E SIM may mediate the interaction between INO80E and 
SUMOylated TFPT. In order to test this hypothesis, we conducted an in vitro binding assay 
to allow us to measure binding between INO80E and SUMO-modified TFPT. We first in 
vitro translated TFPT in the presence of [
35
S]-methionine, then incubated the reaction either 
with or without SUMO1 or SUMO2 and the E1 and E2 SUMO ligases, to give us a mixture 
of unmodified and SUMO-modified TFPT (Figure 10A). We then used this protein mixture 
to conduct binding assays with purified recombinant GST-INO80E bound to glutathione 
sepharose. Although the mixture of TFPT and SUMO2-modified TFPT forms contained a 
larger fraction of the unmodified form than the SUMOylated form, following binding to 
GST-INO80E, we almost exclusively recovered the SUMO2-modified form of TFPT, 
suggesting that INO80E preferentially interacts with the SUMOylated form of TFPT.  
 
When we conducted a binding reaction using the INO80E ΔC10 mutant lacking the 
C-terminal SIM, we saw a reduction in the recovery of SUMOylated TFPT. We then 
repeated this experiment in triplicate and found a significant quantitative reduction in binding 
of the ΔC10 mutant to the SUMO2-modified form of TFPT, while binding to the SUMO1-
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modified form of TFPT was not significantly reduced (Figure 10B). Additionally, the ΔC10 
mutant did not show any difference in its interaction with unmodified TFPT, relative to 
wildtype INO80E (data not shown). This suggests that the C-terminal SIM of TFPT is 
specifically required for binding to the SUMO2-modified form of TFPT. 
 
Next, we wanted to determine whether the INO80E C-terminal SIM was important 
for the interaction between INO80E and TFPT in mammalian cells. We conducted co-
immunoprecipitation experiments in HEK293T cells to look at the interaction between 
INO80E and TFPT. We transfected cells with myc-INO80E and V5-TFPT followed by 
immunoprecipitation using the anti-myc antibody and western blot using anti-V5 showed that 
INO80E could co-immunoprecipitate both the wildtype and K216R mutant forms of TFPT 
(Figure 6C).  However, when we co-transfected the INO80E ΔC10 mutant with TFPT, 
despite equal levels of expression of the INO80E mutant relative to the wildtype form and 
equal immunoprecipitation efficiency, we observed a greatly reduced ability of this mutant 
form of INO80E to co-immunoprecipitate TFPT. We were unable to detect the SUMO-
modified form of TFPT in the co-immunoprecipitated fraction, likely due to the low 
stoichiometry of this form in transfected cells. In mammalian cells it appears that the 
interaction between INO80E and TFPT may be dependent on the INO80E SIM regardless of 
the SUMOylation state of TFPT. This could indicate that the INO80E SIM may be required 
for interaction with unmodified TFPT or alternatively, with another endogenous SUMO-




Finally we co-transfected INO80E wildtype and mutant forms with TFPT and 
SUMO2. We observed a rescue of the interaction between INO80E and TFPT specific to the 
interaction between wildtype INO80E and TFPT that was not observed when co-transfecting 
INO80E delta C10 and TFPT, suggesting that SUMO2 stimulated the INO80E-TFPT 
interaction and that the INO80E SIM was important for this effect. 
 
 We also looked at the interaction between TFPT and the ATPase subunit of the 
INO80 complex, INO80. Previously, it was found that both INO80E and TFPT interacted 
with an N-terminal region of INO80 [116]. We co-transfected a FLAG-tagged N-terminal 
region of INO80, V5-TFPT, and myc-SUMO2 into HCT116 cells and immunoprecipitated 
INO80, followed by immunoblot analysis with antibodies to myc and V5 (Figure 13). We 
found that the fraction of TFPT that was co-immunoprecipitated by INO80 was strongly 
enriched for SUMOylated TFPT. This demonstrated that SUMOylated TFPT was a likely 




We have identified that the interaction between the INO80 chromatin remodeling 
complex subunits INO80E and TFPT is modulated by SUMO. This suggests a potential 
mode of regulating the associated INO80 chromatin remodeling complex. Although the roles 
of the INO80E and TFPT subunits in modulating the INO80 complex are unknown, they 
have been proposed to serve a regulatory function that is likely specific to metazoans, as 
there are no known orthologs in yeast [116]. We confirmed the results of a human proteome 
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microarray-based screen to identify SUMO E3 ligase-dependent SUMOylation substrates 
that showed that the SUMOylation of TFPT is enhanced by the SUMO E3 ligases PIAS1 and 
PIAS3 [143]. We also identified the SUMOylation site at K216. After we identified this site, 
an effort to map SUMOylation sites proteome-wide in HeLa cells confirmed K216 as the 
SUMOylation site on TFPT [126]. We found that INO80E binds to both SUMO1 and 
SUMO2, but a C-terminal SUMO interaction motif appears to be particularly important for 
its interaction with SUMO2. Furthermore, INO80E shows a strong preference for interacting 
with SUMO2-modified TFPT over unmodified TFPT in vitro and this interaction is 
quantitatively reduced following mutation of the INO80E SIM. Interestingly, PIAS1 and 
PIAS3 have been identified as upstream regulators of chromatin remodeling through their 
role in stimulating SUMOylation of the protein MBD1, thus effecting its ability to interact 
with the histone methyltransferase SETDB1 [147]. Thus, PIAS1 and PIAS3-mediated 
SUMOylation of chromatin-associated proteins may be a general mechanism by which 
chromatin remodeling complex assembly is regulated. Together, our work suggests a model 
by which PIAS1 and PIAS3 SUMO E3 ligases promote SUMOylation of TFPT, which 
stimulates association with INO80E in the process of INO80 complex assembly.  
There is some evidence to suggest TFPT may function as a transcription factor. TFPT 
was reported to contain a b-ZIP domain [115], and it was found to possess sequence-specific 
DNA binding activity in a screen to identify DNA binding proteins using a transcription 
factor protein microarray [8]. The transcription factor YY1, a known SUMO target, was 
shown to recruit the INO80 complex to specific gene promoters [92, 148]. TFPT may play a 
similar role, by binding to both the genome and to the INO80 complex in order to recruit the 
complex to specific genomic locations to regulate chromatin remodeling and thus modulate 
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transcription. This could be mediated through the interaction between TFPT and INO80E. 
This is a particularly attractive hypothesis considering the well-established role of 
SUMOylation in regulating transcription factor activity through modulating assembly of 
multiprotein complexes. 
 A recent study found that knockdown of the INO80 ATPase, as well as the other 
INO80 complex subunits INO80E and TFPT, resulted in embryonic stem cell differentiation 
as measured by an ESC-specific reporter assay as well as loss of ESC morphology [149]. 
Additionally, knockdown of INO80E in mouse embryonic stem cells resulted in significant 
gene expression changes in >1200 genes as measured by a DNA microarray [149]. 
Interestingly, the INO80 complex was found to regulate the key pluripotency factor Sox2 and 
occupy multiple locations on the Sox2 gene in mouse embryonic stem cells. Additionally, a 
YY1 binding site identified by the ENCODE project [150] also overlaps with a TFPT DNA 
target sequence identified previously [8] in the orthologous region of the human genome. 
This data points to a potential role of both TFPT and YY1 working redundantly to recruit the 




SUMO binding assay on human proteome microarrays 
 
SUMO binding experiments were conducted with 4 probes representing the SUMO1, 
SUMO2 and the SUMO1 and SUMO2 trimers, all in triplicate. Protein chips were incubated 
overnight in blocking buffer buffer (20 mM HEPES-KOH pH 7.3, 100 mM potassium 
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acetate, 2 mM magnesium acetate, 1 mM EGTA, 0.05% Tween-20, 2% BSA) at 4° C. Chips 
were then incubated with SUMO1 or SUMO2 monomer or trimer in assay buffer (20 mM 
HEPES-KOH pH 7.3, 100 mM potassium acetate, 2 mM magnesium acetate, 1 mM EGTA, 
0.05% Tween-20) for 1 hr at room temperature. Following incubation with SUMO, chips 
were washed 3X with assay buffer and 3X with PBS, followed by incubation with DyLight 
549-anti-SUMO1 (21C7) or DyLight 649-anti-SUMO2 (8A2). Negative control experiments 
were done in parallel using antibodies only without SUMO. Chips were then washed 3X with 
1X TBS with 0.05% Tween-20, 1X with water, then spun to dry and scanned. 
 
Immunoprecipitation and Immunoblot 
 
HEK 293T cells were transfected with Fugene 6 (Promega) and HCT 116 cells were 
transfected with Fugene HD (Promega). Both cell types were plated in 6-well plates, and 
harvested 24-48 hours following transfection. In order to detect protein SUMOylation, cells 
were washed with 1X PBS, then lysed in SUMO IP lysis buffer (50 mM Tris-HCl pH 7.4, 
150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, 20 mM N-ethyl-
maleimide, 1% SDS, and Roche protease inhibitor cocktail) for 10 minutes at 4° C. Then 
SUMO IP bind buffer was added to dilute lysate 1:10 and lysates were transferred to cold 
microcentrifuge tubes. Cells were then sonicated on ice and centrifuged at 15,000 g at 4° C 
for 10 minutes. Soluble cell lysates were incubated with dynabeads (Life Technologies) pre-
bound to either anti-Flag (F1804, Sigma), anti-myc (R95025, Life Technologies), or anti-V5 
(R9605, Life Technologies) antibodies for 2 hours at 4° C and washed 3 times with SUMO 
IP wash buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 2mM EDTA, 1% Triton X-100, 
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0.5% sodium deoxycholate, and 0.1% SDS). Bound proteins were eluted with 1X LDS-
sample buffer (NP0008, Life Technologies) with 5% beta-mercaptoethanol. In order to look 
at protein interactions between INO80E and TFPT by co-immunoprecipitation, cells were 
transfected and harvested as above but lysed in INO80 lysis buffer (40 mM HEPES-NaOH 
pH 7.9, 0.3 M NaCl, 0.2% Triton X-100, and 10% glycerol), followed by centrifugation. 
Lysate supernatants were then bound to dynabeads linked to anti-FLAG or anti-V5 for 2 
hours at 4° C and washed 3X with INO80 wash buffer (40 mM HEPES-NaOH 7.9, 0.25 M 
NaCl, 0.2% Triton X-100, and 10% glycerol). In both immunoprecipitation to detect 
SUMOylated proteins and coimmunoprecipitation experiments to detect interacting proteins, 
samples were resolved on 4-12% NuPage Bis-Tris gels (Life Technologies) in MES buffer 





GST, GST-tagged SUMO1, SUMO2, and SUMO1 and SUMO2 trimers were 
expressed in bacteria and GST-INO80E was expressed in yeast. All GST-tagged proteins 
were purified by affinity chromatography on glutathione sepharose 4B beads (GE 







In vitro binding assays 
 
Recombinant GST, GST-tagged SUMO1, SUMO2, or SUMO2 trimer were diluted 
into 100 ul of 1X PBS, 0.05% Tween 20 and incubated with either glutathione-sepharose or 
alternatively glutathione-coated 96-well plates (Pierce Biotechnology). Following overnight 
incubation at 4 C, wells were blocked for 1 hr at room temperature with 2% bovine serum 
albumin in assay buffer (20 mM HEPES-KOH pH 7.3, 100 mM potassium acetate, 2 mM 
magnesium acetate, 1 mM EGTA, 0.05% Tween-20). INO80E and TFPT were produced by 
in vitro transcription and translation in rabbit reticulocyte lysate in the presence of [
35
S] 
methionine according to manufacturer’s instructions (Promega). In vitro translated proteins 
(10 μl) were diluted into 100 μl of assay buffer, when appropriate, incubated with SUMO1 or 
SUMO2 and the SUMO E1 and E2 enzymes, then incubated with the immobilized GST-
tagged proteins for 1 hr at room temperature. Unbound proteins were removed by washing 
and bound proteins were eluted with SDS sample buffer and resolved by SDS-PAGE and 
autoradiography. Equal loading of immobilized proteins was verified by staining with 
SimplyBlue SafeStain (Life Technologies). Quantitative binding was determined by scanning 
densitometry measurements of radiolabeled protein relative to the amount of binding partner 
protein as indicated by Coomassie stain. 
 
In vitro SUMOylation assays 
 
TFPT was produced by in vitro transcription and translation in rabbit reticulocute 
lysate in the presence of [
35
S] methionine according to manufacturer’s instructions (Promega). 
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Radiolabeled protein was then incubated with our without SUMO1 or SUMO2 and the 
SUMO E1 and E2 enzymes for 1 hour at 37° C to yield a mixture of SUMOylated and 
unmodified TFPT for subsequent binding experiments. 
 
Protein Microarray Data Analysis 
 
To identify positive hits for each chip, first bad spots were removed, such as spots in 
a damaged region of the chip, as measured by a coefficient of variation (CV) value >1.5. A 
background correction was then applied, defined as the signal intensity (SI) value of each 
spot as the odds ratio of the foreground median divided by the background median. If a spot 
has a weak signal, its foreground median and background median will be close, thus its SI 
will be ~1. To normalize the signal, we suppose the true hits are rare and almost evenly 
dispersed in each block, thus we force each block on a chip to have a median SI of one. To be 
considered a positive hit, the duplicate spots of each protein must both have signal intensities 
(foreground/background ratio) 5 SD above the mean value. Additionally, positive hits must 
occur in 2 out of 3 triplicate experiments to be considered positive. Positive hits also 
identified in negative control chips were removed.  
 
Network Motif Analysis 
 
Protein microarray data from both SUMO-binding experiments and SUMOylation 
experiments [143] was integrated with protein-protein interaction data from publicly 
available databases, including BioGRID, DIP, MIPS, IntAct and HPRD and network motifs 
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were identified and analyzed as previously described [144]. The Z-value of a motif was 
calculated as the difference of its observed occurrence in a real network and its averaged 


















Figure 10. Venn diagram of SUMO-binding proteins identified here and in previous 
work. This illustrates the overlap between our dataset compared to proteins identified by 
Ouyang et al. [112] and other SUMO-binding proteins previously identified in the literature, 
which consists of a list of SUMO-binding proteins compiled by Zhao et al. [146] along with 













Figure 11. TFPT specifically binds the SUMO2 trimer in vitro. Results of in vitro binding 
assay showing specific binding of INO80E to the SUMO2 trimer. BLM, a known SUMO2 









Figure 13. The INO80 ATPase N-terminal domain binds SUMOylated TFPT. Results of 
an in vivo binding assay. HCT116 cells were co-transfected with an N-terminal fragment of 
INO80 (1-406), SUMO2 and TFPT. We immunoprecipitated FLAG-tagged INO80 and 
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